{"text_format":"1","workbook":"xlsx","n_sheets":3,"sheets":["Cover page","Introduction","Database"],"not_rendered":{"charts":0,"images":1,"macros":1,"external_links":1,"defined_names":4,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900"}

{"sheet":"Cover page","index":0,"n_rows":0,"n_cols":0,"rows_kept":0,"cut":false,"hidden":false,"merged":[]}

{"sheet":"Introduction","index":1,"n_rows":12,"n_cols":2,"rows_kept":12,"cut":false,"hidden":false,"merged":[]}
[]
[null,"Introduction"]
[null,"The following spreadsheet provides estimates of the effect of NICE recommended drugs, compared to placebo, on specific outcomes, in specific conditions."]
[null,"The evidence used to generate these estimates is the same evidence used by NICE to develop the recommendations to use these drugs. This re-presentation of the data does not affect the recommendations. These recommendations were typically made in single condition guidelines and are not necessarily appropriate for people with multimorbidity."]
[null,"This tool is designed to inform discussions between patient and clinician when considering the benefits and harms of taking long term medication."]
[null,"The information here is principally designed to give an order of magnitude estimate of efficacy. A number of assumptions and caveats were necessary to generate these estimates and they should not be used beyond their limitations."]
[null,"The trials from which this evidence is derived typically do not include people with multimorbidity. Users of the database should take this into account when assessing the likely benefit of a treatment for any one individual."]
[]
[null,"To access the database click on the database tab below or press \"Ctrl + Page Down\""]
[]
[]
[null,"© National Institute for Health and Care Excellence, 2016. All rights reserved. NICE copyright material can be downlaoded for private research and study, and may be reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the written permission of NICE."]

{"sheet":"Database","index":2,"n_rows":66,"n_cols":74,"rows_kept":66,"cut":false,"hidden":false,"merged":[]}
[]
["Condition","Drug","Outcome","Outcome for text (plural)","Outcome for text (singular)","Event (n) in intervention group","Total n in intervention group","Event rate intervention group (%)","Event rate control group ","Total n control group","Event rate control group (%) ","Median study duration (days)","Relative risk (RR; as reported)","Relative risk lower CI (RR; as reported)","Relative risk upper CI (RR; as reported)","Relative risk less effective CI (RR; as reported)","Relative risk more effective CI (RR; as reported)","Outcome direction","RR CI cross LoNE","Absolute benefit (per 1000 patients)","Absolute benefit lower CI (per 1000 patients)","Absolute difference upper CI (per 1000 patients)","Absolute benefit (per 1000 patients, per year)","Absolute benefit lower CI (per 1000 patients, per year)","Absolute difference upper CI (per 1000 patients, per year)","Trial duration risk with treatment","Trial duration risk with treatment low CI","Trial duration risk with treatment high CI","Annual risk with treatment","Annual risk with treatment low CI","Annual risk with treatment high CI","Absolute risk change with treatment","Absolute risk reduction lower CI","Absolute risk reduction upper CI","Absolute risk reduction ann","Absolute risk reduction ann lower CI","Absolute risk reduction annupper CI","NNT","NNT lower CI","NNT upper CI","Annualised NNT","Annualised NNT lower CI","Annualised NNT upper CI",null,null,"Relative risk  reduction","NNT (relative risk reduction)",null,"HR (as reported)","HR lower CI","HR upper CI","RR (calculated from HR)","RR lower CI (as calculated from HR)","RR upper CI (as calculated from HR)",null,"Condition (subpopulation)","Drug","Comparison","Outcome (P = positive, N = negative)","Median duration of studies (years)","Patients experiencing outcome in control group/baseline risk","Annualised baseline risk","Relative risk with treatment vs placebo (95% CI)","Absolute difference in outcomes if 1000 people are treated for duration of trials (95% CI)","Absolute difference in outcomes if 1000 people are treated per year (95% CI)","\"Number needed to treat\" for the duration of trials (95% CI)","\"Number needed to treat\" per year (95% CI)","\"Number needed to treat\" for the duration of trials (modified CI)","\"Number needed to treat\" per year (modified CI)","Absolute change in risk by treatment for the duration of the trials (95% CI)","Absolute change in risk by treatment per year (95% CI)","NICE Recommends","Links to guidelines","Trial population details"]
["Atrial fibrillation","Anticoagulant","All ischaemic stroke","ischaemic strokes","ischaemic stroke",24,1175,{"$f":"ROUND((F3/G3)*100, 2)","v":2.04},null,null,3.7,365,0.33,0.21,0.53,{"$f":"IF(R3=\"N\", O3, N3)","v":0.53},{"$f":"IF(R3=\"N\", N3, O3)","v":0.21},"N",{"$f":"IF(OR((AND(M3>1, Q3<1)),(AND(M3<1,P3>1))),1,0)","v":0},{"$f":"IF($F3=\"\", ROUND((#REF!*10)*(1-M3), 0), ROUND(($K3*10)*(1-M3), 0))","v":25},{"$f":"IF($F3=\"\", ROUND((#REF!*10)*(1-P3), 0), ROUND(($K3*10)*(1-P3), 0))","v":17},{"$f":"IF($F3=\"\", ROUND((#REF!*10)*(1-Q3), 0), ROUND(($K3*10)*(1-Q3), 0))","v":29},{"$f":"ROUND((T3/(L3/365)), 0)","v":25},{"$f":"ROUND((U3/(L3/365)), 0)","v":17},{"$f":"ROUND((V3/(L3/365)), 0)","v":29},{"$f":"($K3*M3)/100","v":1.221E-2},{"$f":"($K3*P3)/100","v":1.9610000000000002E-2},{"$f":"($K3*Q3)/100","v":7.77E-3},{"$f":"Z3/($L3/365)","v":1.221E-2},{"$f":"AA3/($L3/365)","v":1.9610000000000002E-2},{"$f":"AB3/($L3/365)","v":7.77E-3},{"$f":"((M3*K3)-K3)/100","v":-2.479E-2},{"$f":"((P3*K3)-K3)/100","v":-1.7389999999999999E-2},{"$f":"((Q3*K3)-K3)/100","v":-2.9229999999999999E-2},{"$f":"ROUND(AF3/($L3/365), 4)","v":-2.4799999999999999E-2},{"$f":"ROUND(AG3/($L3/365), 4)","v":-1.7399999999999999E-2},{"$f":"ROUND(AH3/($L3/365), 4)","v":-2.92E-2},{"$f":"ROUND(1/-AF3, 0)","v":40},{"$f":"ROUND(1/-AG3, 0)","v":58},{"$f":"ROUND(1/-AH3, 0)","v":34},{"$f":"ROUND((AL3*L3)/365, 0)","v":40},{"$f":"ROUND((AM3*L3)/365, 0)","v":58},{"$f":"ROUND((AN3*L3)/365, 0)","v":34},null,null,{"$f":"(K3-H3)/K3","v":0.44864864864864867},{"$f":"100/(K3*AT3)","v":60.240963855421683},null,null,null,null,{"$f":"(1-EXP(AW3*LN(1-(K3/100))))/(K3/100)","v":0},{"$f":"(1-EXP(AX3*LN(1-(K3/100))))/(K3/100)","v":0},{"$f":"(1-EXP(AY3*LN(1-(K3/100))))/(K3/100)","v":0},null,{"$f":"A3","v":"Atrial fibrillation"},{"$f":"B3","v":"Anticoagulant"},"Placebo",{"$f":"CONCATENATE(C3, \" (\", R3, \")\")","v":"All ischaemic stroke (N)"},{"$f":"IF(L3/365=0, \"N/A\", ROUND(L3/365, 1))","v":1},{"$f":"IFERROR(IF(I3<>\"\", CONCATENATE(I3, \"/\", J3, \" (\", K3, \"%)\"), CONCATENATE(K3, \"%\")), \"N/A\")","v":"3.7%"},{"$f":"IFERROR((K3*(365/L3))/100, \"N/A\")","v":3.7000000000000005E-2},{"$f":"IF(M3=\"\", \"N/A\", CONCATENATE(M3, \" (\", P3, \" to \", Q3, \")\"))","v":"0.33 (0.53 to 0.21)"},{"$f":"IFERROR(CONCATENATE(IF(T3>0, T3, -T3), IF(T3>0, CONCATENATE(\" fewer \", D3, \" per 1000 people treated for \"), CONCATENATE(\" more \", D3, \" per 1000 people treated for \")), BH3,\" year(s) \", \"(from \", IF(U3>0, U3,-U3), IF(U3>0, \" fewer to \", \" more to \"), IF(V3>0, V3, -V3), IF(V3>0, \" fewer)\", \" more)\")), \"N/A\")","v":"25 fewer ischaemic strokes per 1000 people treated for 1 year(s) (from 17 fewer to 29 fewer)"},{"$f":"IFERROR(CONCATENATE(IF(W3>0, W3, -W3), IF(W3>0, CONCATENATE(\" fewer \", D3, \" per 1000 people treated per year\"), CONCATENATE(\" more \", D3, \" per 1000 people treated per year\")), \" (from \", IF(X3>0, X3,-X3), IF(X3>0, \" fewer to \", \" more to \"), IF(Y3>0, Y3, -Y3), IF(Y3>0, \" fewer)\", \" more)\")), \"N/A\")","v":"25 fewer ischaemic strokes per 1000 people treated per year (from 17 fewer to 29 fewer)"},{"$f":"IFERROR((IF(R3=\"N\", (CONCATENATE(\"Need to treat \", IF(AL3>0, AL3, -AL3), \" people for \", BH3, \" year(s) to \", IF(AL3>0, CONCATENATE(\"prevent one \", E3), CONCATENATE(\"cause one \", E3)), \" (from treating \", IF(AM3>0, AM3, -AM3), \" people to \", IF(AM3>0, \"prevent one to treating \", \"cause one to treating \"), IF(AN3>0, AN3, -AN3), IF(AN3>0, \" people to prevent one)\", \" people to cause one)\"))), (CONCATENATE(\"Need to treat \", IF(AL3<0, -AL3, AL3), \" people for \", BH3, \" year(s) to \", IF(AL3<0, CONCATENATE(\"achieve one \", E3), CONCATENATE(\"fail to achieve one \", E3)), \" (from treating \", IF(AM3<0, -AM3, AM3), IF(AM3<0, \" people to achieve one \", \" people to fail to achieve one \"),\"to treating \", IF(AN3<0,-AN3, AN3), IF(AN3<0, \" people to achieve one)\", \" people to fail to achieve one)\"))))), \"N/A\")","v":"Need to treat 40 people for 1 year(s) to prevent one ischaemic stroke (from treating 58 people to prevent one to treating 34 people to prevent one)"},{"$f":"IFERROR((IF(R3=\"N\", (CONCATENATE(\"Need to treat \", IF(AO3>0, AO3, -AO3), \" people for 1 year to \", IF(AO3>0, CONCATENATE(\"prevent one \", E3), CONCATENATE(\"cause one \", E3)), \" (from treating \", IF(AP3>0, AP3, -AP3), \" people to \", IF(AP3>0, \"prevent one to treating \", \" cause one to treating \"), IF(AQ3>0, AQ3, -AQ3), IF(AQ3>0, \" people to prevent one)\", \" people to cause one)\"))), (CONCATENATE(\"Need to treat \", IF(AO3<0, -AO3, AO3), IF(AO3<0, CONCATENATE(\" people for 1 year to achieve one \", E3), CONCATENATE(\" people for 1 year to fail to achieve one \", E3)), \" (from treating \", IF(AP3<0, -AP3, AP3), IF(AP3<0, \" people to achieve one to treating \", \" people to fail to achieve one \"),\"to treating \", IF(AQ3<0,-AQ3, AQ3), IF(AQ3<0, \" people to achieve one)\", \" people to fail to achieve one)\"))))), \"N/A\")","v":"Need to treat 40 people for 1 year to prevent one ischaemic stroke (from treating 58 people to prevent one to treating 34 people to prevent one)"},{"$f":"IFERROR((IF(R3=\"N\", (CONCATENATE(\"Need to treat \", IF(AL3>0, AL3, -AL3), \" people for \", BH3, \" year(s) to \", IF(AL3>0, CONCATENATE(\"prevent one \", E3), CONCATENATE(\"cause one \", E3)), IF(S3=0, CONCATENATE(\" (from treating \", IF(AM3>0, AM3, -AM3), \" people to \", IF(AM3>0, \"prevent one to treating \", \"cause one to treating \"), IF(AN3>0, AN3, -AN3), IF(AN3>0, \" people)\", \" people)\")), \" (confidence intervals crossed the line of no effect)\"))), (CONCATENATE(\"Need to treat \", IF(AL3<0, -AL3, AL3), \" people for \", BH3, \" year(s) to \", IF(AL3<0, CONCATENATE(\"achieve one \", E3), CONCATENATE(\"fail to achieve one \", E3)), IF(S3=0, CONCATENATE(\" (from treating \", IF(AM3<0, -AM3, AM3), IF(AM3<0, \" people to achieve one \", \" people to fail to achieve one \"),\"to treating \", IF(AN3<0,-AN3, AN3), IF(AN3<0, \" people)\", \" people)\")), \" (Confidence intervals crossed the line of no effect)\"))))), \"N/A\")","v":"Need to treat 40 people for 1 year(s) to prevent one ischaemic stroke (from treating 58 people to prevent one to treating 34 people)"},{"$f":"IFERROR((IF(R3=\"N\", (CONCATENATE(\"Need to treat \", IF(AO3>0, AO3, -AO3), \" people for 1 year to \", IF(AO3>0, CONCATENATE(\"prevent one \", E3), CONCATENATE(\"cause one \", E3)), IF(S3=0, CONCATENATE(\" (from treating \", IF(AP3>0, AP3, -AP3), \" people to \", IF(AP3>0, \"prevent one to treating \", \" cause one to treating \"), IF(AQ3>0, AQ3, -AQ3), IF(AQ3>0, \" people)\", \" people)\")), \" (confidence intervals crossed the line of no effect)\"))), (CONCATENATE(\"Need to treat \", IF(AO3<0, -AO3, AO3), IF(AO3<0, CONCATENATE(\" people for 1 year to achieve one \", E3), CONCATENATE(\" people for 1 year to fail to achieve one \", E3)), IF(S3=0, CONCATENATE(\" (from treating \", IF(AP3<0, -AP3, AP3), IF(AP3<0, \" people to achieve one to treating \", \" people to fail to achieve one \"),\"to treating \", IF(AQ3<0,-AQ3, AQ3), IF(AQ3<0, \" people)\", \" people)\")), \" (confidence intervals crossed the line of no effect)\"))))), \"N/A\")","v":"Need to treat 40 people for 1 year to prevent one ischaemic stroke (from treating 58 people to prevent one to treating 34 people)"},{"$f":"IFERROR(CONCATENATE((100*ROUND($AF3, 4)), \"% absolute change in risk of \", E3, \" per \", BH3, \" year(s) \", \"(from \", 100*ROUND($AH3, 4), \"% to \", (100*ROUND($AG3, 4)), \"%)\"), \"N/A\")","v":"-2.48% absolute change in risk of ischaemic stroke per 1 year(s) (from -2.92% to -1.74%)"},{"$f":"IFERROR(CONCATENATE((100*ROUND($AI3, 4)), \"% absolute change in risk of \", D3, \" per year\",\" (from \", 100*ROUND($AK3, 4), \"% to \", (100*ROUND($AJ3, 4)), \"%)\"), \"N/A\")","v":"-2.48% absolute change in risk of ischaemic strokes per year (from -2.92% to -1.74%)"},"Consider anticoagulation for men with a CHA2DS2-VASc score of 1. Take the bleeding risk into account. Offer anticoagulation to people with a CHA2DS2-VASc score of 2 or above, taking bleeding risk into account. ","Taken from recommendations 1.5.2 and 1.5.3 of the NICE guideline on atrial fibrillation.","5 trials, mean ages ranging from 67 to 74, excluded patients who had previously had a stroke or TIA"]
["Atrial fibrillation","Anticoagulant","All cause mortality","deaths","death",115,1471,7.82,147,1475,{"$f":"ROUND((I4/J4)*100, 2)","v":9.9700000000000006},{"$f":"365*2","v":730},0.78,0.62,0.98,{"$f":"IF(R4=\"N\", O4, N4)","v":0.98},{"$f":"IF(R4=\"N\", N4, O4)","v":0.62},"N",0,{"$f":"IF($F4=\"\", ROUND((#REF!*10)*(1-M4), 0), ROUND(($K4*10)*(1-M4), 0))","v":22},{"$f":"IF($F4=\"\", ROUND((#REF!*10)*(1-P4), 0), ROUND(($K4*10)*(1-P4), 0))","v":2},{"$f":"IF($F4=\"\", ROUND((#REF!*10)*(1-Q4), 0), ROUND(($K4*10)*(1-Q4), 0))","v":38},11,1,19,{"$f":"($K4*M4)/100","v":7.7766000000000016E-2},{"$f":"($K4*P4)/100","v":9.7706000000000001E-2},{"$f":"($K4*Q4)/100","v":6.1814000000000001E-2},{"$f":"Z4/($L4/365)","v":3.8883000000000008E-2},{"$f":"AA4/($L4/365)","v":4.8853000000000001E-2},{"$f":"AB4/($L4/365)","v":3.0907E-2},-2.1933999999999995E-2,-1.9940000000000071E-3,-3.7886000000000003E-2,{"$f":"ROUND(AF4/($L4/365), 4)","v":-1.0999999999999999E-2},{"$f":"ROUND(AG4/($L4/365), 4)","v":-1E-3},{"$f":"ROUND(AH4/($L4/365), 4)","v":-1.89E-2},{"$f":"ROUND(1/-AF4, 0)","v":46},{"$f":"ROUND(1/-AG4, 0)","v":502},{"$f":"ROUND(1/-AH4, 0)","v":26},92,1004,52,null,null,0.21564694082246744,46.511627906976734,null,null,null,null,{"$f":"(1-EXP(AW4*LN(1-(K4/100))))/(K4/100)","v":0},{"$f":"(1-EXP(AX4*LN(1-(K4/100))))/(K4/100)","v":0},{"$f":"(1-EXP(AY4*LN(1-(K4/100))))/(K4/100)","v":0},null,"Atrial fibrillation","Anticoagulant","Placebo",{"$f":"CONCATENATE(C4, \" (\", R4, \")\")","v":"All cause mortality (N)"},2,"147/1475 (9.97%)",4.9850000000000005E-2,"0.78 (0.98 to 0.62)","22 fewer deaths per 1000 people treated for 2 year(s) (from 2 fewer to 38 fewer)","11 fewer deaths per 1000 people treated per year (from 1 fewer to 19 fewer)","Need to treat 46 people for 2 year(s) to prevent one death (from treating 502 people to prevent one to treating 26 people to prevent one)","Need to treat 92 people for 1 year to prevent one death (from treating 1004 people to prevent one to treating 52 people to prevent one)","Need to treat 46 people for 2 year(s) to prevent one death (from treating 502 people to prevent one to treating 26 people)","Need to treat 92 people for 1 year to prevent one death (from treating 1004 people to prevent one to treating 52 people)","-2.19% absolute change in risk of death per 2 year(s) (from -3.79% to -0.2%)","-1.1% absolute change in risk of deaths per year (from -1.89% to -0.1%)","Consider anticoagulation for men with a CHA2DS2-VASc score of 1. Take the bleeding risk into account. Offer anticoagulation to people with a CHA2DS2-VASc score of 2 or above, taking bleeding risk into account. ","Taken from recommendations 1.5.2 and 1.5.3 of the NICE guideline on atrial fibrillation.","6 trials, mean ages ranging from 67 to 74, 5 trials excluded patients who had previously had a stroke or TIA, 1 trial included only those with a previous stroke or TIA"]
["Chronic kidney disease","ACE inhibitors","All cause mortality","deaths","death",644,6981,9.23,null,null,7.5,{"$f":"ROUND(4.6*365, 0)","v":1679},0.96,0.86,1.06,1.06,0.86,"N",{"$f":"IF(OR((AND(M5>1, Q5<1)),(AND(M5<1,P5>1))),1,0)","v":1},{"$f":"IF($F5=\"\", ROUND((#REF!*10)*(1-M5), 0), ROUND(($K5*10)*(1-M5), 0))","v":3},{"$f":"IF($F5=\"\", ROUND((#REF!*10)*(1-P5), 0), ROUND(($K5*10)*(1-P5), 0))","v":-5},{"$f":"IF($F5=\"\", ROUND((#REF!*10)*(1-Q5), 0), ROUND(($K5*10)*(1-Q5), 0))","v":11},1,-1,2,7.1999999999999995E-2,7.9500000000000001E-2,6.4500000000000002E-2,1.5652173913043479E-2,1.7282608695652176E-2,1.4021739130434785E-2,-3.000000000000007E-3,4.5000000000000014E-3,-1.0499999999999999E-2,-6.9999999999999999E-4,1E-3,-2.3E-3,333,-222,95,1532,-1021,437,null,null,-0.23066666666666671,-57.803468208092468,null,null,null,null,{"$f":"(1-EXP(AW5*LN(1-(K5/100))))/(K5/100)","v":0},{"$f":"(1-EXP(AX5*LN(1-(K5/100))))/(K5/100)","v":0},{"$f":"(1-EXP(AY5*LN(1-(K5/100))))/(K5/100)","v":0},null,"Chronic kidney disease","ACE inhibitors","Placebo","All cause mortality (N)",4.5999999999999996,"7.5%",1.6304347826086956E-2,"0.96 (1.06 to 0.86)","3 fewer deaths per 1000 people treated for 4.6 year(s) (from 5 more to 11 fewer)","1 fewer deaths per 1000 people treated per year (from 1 more to 2 fewer)",{"$f":"IFERROR((IF(R5=\"N\", (CONCATENATE(\"Need to treat \", IF(AL5>0, AL5, -AL5), \" people for \", BH5, \" year(s) to \", IF(AL5>0, CONCATENATE(\"prevent one \", E5), CONCATENATE(\"cause one \", E5)), \" (from treating \", IF(AM5>0, AM5, -AM5), \" people to \", IF(AM5>0, \"prevent one to treating \", \"cause one to treating \"), IF(AN5>0, AN5, -AN5), IF(AN5>0, \" people to prevent one)\", \" people to cause one)\"))), (CONCATENATE(\"Need to treat \", IF(AL5<0, -AL5, AL5), \" people for \", BH5, \" year(s) to \", IF(AL5<0, CONCATENATE(\"achieve one \", E5), CONCATENATE(\"fail to achieve one \", E5)), \" (from treating \", IF(AM5<0, -AM5, AM5), IF(AM5<0, \" people to achieve one \", \" people to fail to achieve one \"),\"to treating \", IF(AN5<0,-AN5, AN5), IF(AN5<0, \" people to achieve one)\", \" people to fail to achieve one)\"))))), \"N/A\")","v":"Need to treat 333 people for 4.6 year(s) to prevent one death (from treating 222 people to cause one to treating 95 people to prevent one)"},{"$f":"IFERROR((IF(R5=\"N\", (CONCATENATE(\"Need to treat \", IF(AO5>0, AO5, -AO5), \" people for 1 year to \", IF(AO5>0, CONCATENATE(\"prevent one \", E5), CONCATENATE(\"cause one \", E5)), \" (from treating \", IF(AP5>0, AP5, -AP5), \" people to \", IF(AP5>0, \"prevent one to treating \", \"cause one to treating \"), IF(AQ5>0, AQ5, -AQ5), IF(AQ5>0, \" people to prevent one)\", \" people to cause one)\"))), (CONCATENATE(\"Need to treat \", IF(AO5<0, -AO5, AO5), IF(AO5<0, CONCATENATE(\" people for 1 year to achieve one \", E5), CONCATENATE(\" people for 1 year to fail to achieve one \", E5)), \" (from treating \", IF(AP5<0, -AP5, AP5), IF(AP5<0, \" people to achieve one to treating \", \" people to fail to achieve one \"),\"to treating \", IF(AQ5<0,-AQ5, AQ5), IF(AQ5<0, \" people to achieve one)\", \" people to fail to achieve one)\"))))), \"N/A\")","v":"Need to treat 1532 people for 1 year to prevent one death (from treating 1021 people to cause one to treating 437 people to prevent one)"},{"$f":"IFERROR((IF(R5=\"N\", (CONCATENATE(\"Need to treat \", IF(AL5>0, AL5, -AL5), \" people for \", BH5, \" year(s) to \", IF(AL5>0, CONCATENATE(\"prevent one \", E5), CONCATENATE(\"cause one \", E5)), IF(S5=0, CONCATENATE(\" (from treating \", IF(AM5>0, AM5, -AM5), \" people to \", IF(AM5>0, \"prevent one to treating \", \"cause one to treating \"), IF(AN5>0, AN5, -AN5), IF(AN5>0, \" people)\", \" people)\")), \" (confidence intervals crossed the line of no effect)\"))), (CONCATENATE(\"Need to treat \", IF(AL5<0, -AL5, AL5), \" people for \", BH5, \" year(s) to \", IF(AL5<0, CONCATENATE(\"achieve one \", E5), CONCATENATE(\"fail to achieve one \", E5)), IF(S5=0, CONCATENATE(\" (from treating \", IF(AM5<0, -AM5, AM5), IF(AM5<0, \" people to achieve one \", \" people to fail to achieve one \"),\"to treating \", IF(AN5<0,-AN5, AN5), IF(AN5<0, \" people)\", \" people)\")), \" (Confidence intervals crossed the line of no effect)\"))))), \"N/A\")","v":"Need to treat 333 people for 4.6 year(s) to prevent one death (confidence intervals crossed the line of no effect)"},{"$f":"IFERROR((IF(R5=\"N\", (CONCATENATE(\"Need to treat \", IF(AO5>0, AO5, -AO5), \" people for 1 year to \", IF(AO5>0, CONCATENATE(\"prevent one \", E5), CONCATENATE(\"cause one \", E5)), IF(S5=0, CONCATENATE(\" (from treating \", IF(AP5>0, AP5, -AP5), \" people to \", IF(AP5>0, \"prevent one to treating \", \" cause one to treating \"), IF(AQ5>0, AQ5, -AQ5), IF(AQ5>0, \" people)\", \" people)\")), \" (confidence intervals crossed the line of no effect)\"))), (CONCATENATE(\"Need to treat \", IF(AO5<0, -AO5, AO5), IF(AO5<0, CONCATENATE(\" people for 1 year to achieve one \", E5), CONCATENATE(\" people for 1 year to fail to achieve one \", E5)), IF(S5=0, CONCATENATE(\" (from treating \", IF(AP5<0, -AP5, AP5), IF(AP5<0, \" people to achieve one to treating \", \" people to fail to achieve one \"),\"to treating \", IF(AQ5<0,-AQ5, AQ5), IF(AQ5<0, \" people)\", \" people)\")), \" (confidence intervals crossed the line of no effect)\"))))), \"N/A\")","v":"Need to treat 1532 people for 1 year to prevent one death (confidence intervals crossed the line of no effect)"},"-0.3% absolute change in risk of death per 4.6 year(s) (from -1.05% to 0.45%)","-0.07% absolute change in risk of deaths per year (from -0.23% to 0.1%)","Offer a low-cost renin-angiotensin system antagonist to people with CKD and diabetes and an ACR of 3 mg/mmol or more OR CKD and hypertension and an ACR of 30 mg/mmol or more OR CKD and an ACR of 70 mg/mmol or more (irrespective of hypertension or cardiovascular disease). ","Taken from recommendation 1.6.3 of the NICE guideline on chronic kidney disease in adults.","5 trials, 3 in patients with T1DM, 1 in patients without diabetes, 1 in patients with stable coronary disease, mean ages ranging from 34.5 to 69, one study mean age not available in guideline\n"]
["Chronic kidney disease","ACE inhibitors","Cardiovascular events","cardiovascular events","cardiovascular event",220,7539,2.92,236,7628,{"$f":"ROUND((I6/J6)*100, 2)","v":3.09},{"$f":"ROUND(4.25*365, 0)","v":1551},0.94,0.79,1.1299999999999999,1.1299999999999999,0.79,"N",{"$f":"IF(OR((AND(M6>1, Q6<1)),(AND(M6<1,P6>1))),1,0)","v":1},{"$f":"IF($F6=\"\", ROUND((#REF!*10)*(1-M6), 0), ROUND(($K6*10)*(1-M6), 0))","v":2},{"$f":"IF($F6=\"\", ROUND((#REF!*10)*(1-P6), 0), ROUND(($K6*10)*(1-P6), 0))","v":-4},{"$f":"IF($F6=\"\", ROUND((#REF!*10)*(1-Q6), 0), ROUND(($K6*10)*(1-Q6), 0))","v":6},0,-1,1,2.9045999999999999E-2,3.4916999999999997E-2,2.4411000000000002E-2,6.8354545454545447E-3,8.2170889748549303E-3,5.7446905222437138E-3,-1.8540000000000002E-3,4.0169999999999954E-3,-6.4889999999999982E-3,-4.0000000000000002E-4,8.9999999999999998E-4,-1.5E-3,539,-249,154,2290,-1058,654,null,null,5.5016181229773441E-2,588.2352941176473,null,null,null,null,{"$f":"(1-EXP(AW6*LN(1-(K6/100))))/(K6/100)","v":0},{"$f":"(1-EXP(AX6*LN(1-(K6/100))))/(K6/100)","v":0},{"$f":"(1-EXP(AY6*LN(1-(K6/100))))/(K6/100)","v":0},null,"Chronic kidney disease","ACE inhibitors","Placebo","Cardiovascular events (N)",4.2,"236/7628 (3.09%)",7.2717601547388775E-3,"0.94 (1.13 to 0.79)","2 fewer cardiovascular events per 1000 people treated for 4.2 year(s) (from 4 more to 6 fewer)","0 more cardiovascular events per 1000 people treated per year (from 1 more to 1 fewer)","Need to treat 539 people for 4.2 year(s) to prevent one cardiovascular event (from treating 249 people to cause one to treating 154 people to prevent one)","Need to treat 2290 people for 1 year to prevent one cardiovascular event (from treating 1058 people to  cause one to treating 654 people to prevent one)","Need to treat 539 people for 4.2 year(s) to prevent one cardiovascular event (confidence intervals crossed the line of no effect)","Need to treat 2290 people for 1 year to prevent one cardiovascular event (confidence intervals crossed the line of no effect)","-0.19% absolute change in risk of cardiovascular event per 4.2 year(s) (from -0.65% to 0.4%)","-0.04% absolute change in risk of cardiovascular events per year (from -0.15% to 0.09%)","Offer a low-cost renin-angiotensin system antagonist to people with CKD and diabetes and an ACR of 3 mg/mmol or more OR CKD and hypertension and an ACR of 30 mg/mmol or more OR CKD and an ACR of 70 mg/mmol or more (irrespective of hypertension or cardiovascular disease). ","Taken from recommendation 1.6.3 of the NICE guideline on chronic kidney disease in adults.","4 trials, 2 in patients with T1DM, 1 in patients with T2DM, 1 in patients without diabetes, mean ages ranging from 40 to 65, one study mean age not available in guideline"]
["Chronic kidney disease","ACE inhibitors","Progression of CKD - change in eGFR","progressions of CKD (change in eGFR)","progression of CKD (change in eGFR)",25,207,12.08,null,null,21.3,{"$f":"3*365","v":1095},0.72,0.56999999999999995,0.92,0.92,0.56999999999999995,"N",0,{"$f":"IF($F7=\"\", ROUND((#REF!*10)*(1-M7), 0), ROUND(($K7*10)*(1-M7), 0))","v":60},{"$f":"IF($F7=\"\", ROUND((#REF!*10)*(1-P7), 0), ROUND(($K7*10)*(1-P7), 0))","v":17},{"$f":"IF($F7=\"\", ROUND((#REF!*10)*(1-Q7), 0), ROUND(($K7*10)*(1-Q7), 0))","v":92},20,6,31,0.15336,0.19596,0.12141,5.1119999999999999E-2,6.5320000000000003E-2,4.0469999999999999E-2,-5.9640000000000006E-2,-1.7040000000000007E-2,-9.1590000000000005E-2,-1.9900000000000001E-2,-5.7000000000000002E-3,-3.0499999999999999E-2,17,59,11,51,177,33,null,null,0.43286384976525821,10.845986984815617,null,0.7,0.54,0.91,{"$f":"ROUND((1-EXP(AW7*LN(1-(K7/100))))/(K7/100), 2)","v":0.72},{"$f":"ROUND((1-EXP(AX7*LN(1-(K7/100))))/(K7/100), 2)","v":0.56999999999999995},{"$f":"ROUND((1-EXP(AY7*LN(1-(K7/100))))/(K7/100), 2)","v":0.92},null,"Chronic kidney disease","ACE inhibitors","Placebo","Progression of CKD - change in eGFR (N)",3,"21.3%",7.0999999999999994E-2,"0.72 (0.92 to 0.57)","60 fewer progressions of CKD (change in eGFR) per 1000 people treated for 3 year(s) (from 17 fewer to 92 fewer)","20 fewer progressions of CKD (change in eGFR) per 1000 people treated per year (from 6 fewer to 31 fewer)","Need to treat 17 people for 3 year(s) to prevent one progression of CKD (change in eGFR) (from treating 59 people to prevent one to treating 11 people to prevent one)","Need to treat 51 people for 1 year to prevent one progression of CKD (change in eGFR) (from treating 177 people to prevent one to treating 33 people to prevent one)","Need to treat 17 people for 3 year(s) to prevent one progression of CKD (change in eGFR) (from treating 59 people to prevent one to treating 11 people)","Need to treat 51 people for 1 year to prevent one progression of CKD (change in eGFR) (from treating 177 people to prevent one to treating 33 people)","-5.96% absolute change in risk of progression of CKD (change in eGFR) per 3 year(s) (from -9.16% to -1.7%)","-1.99% absolute change in risk of progressions of CKD (change in eGFR) per year (from -3.05% to -0.57%)","Offer a low-cost renin-angiotensin system antagonist to people with CKD and diabetes and an ACR of 3 mg/mmol or more OR CKD and hypertension and an ACR of 30 mg/mmol or more OR CKD and an ACR of 70 mg/mmol or more (irrespective of hypertension or cardiovascular disease). ","Taken from recommendation 1.6.3 of the NICE guideline on chronic kidney disease in adults.","1 trial, patients with T1DM, mean age 34.5"]
["Chronic kidney disease","ACE inhibitors","Progression of CKD - occurrence of ESRD","progressions of CKD (occurrence of ESRD)","progression of CKD (occurrence of ESRD)",28,2666,1.05,null,null,15.5,{"$f":"ROUND(3*365, 0)","v":1095},0.61,0.39,0.95,0.95,0.39,"N",0,{"$f":"IF($F8=\"\", ROUND((#REF!*10)*(1-M8), 0), ROUND(($K8*10)*(1-M8), 0))","v":60},{"$f":"IF($F8=\"\", ROUND((#REF!*10)*(1-P8), 0), ROUND(($K8*10)*(1-P8), 0))","v":8},{"$f":"IF($F8=\"\", ROUND((#REF!*10)*(1-Q8), 0), ROUND(($K8*10)*(1-Q8), 0))","v":95},20,3,32,9.4549999999999995E-2,0.14724999999999999,6.0449999999999997E-2,3.1516666666666665E-2,4.9083333333333333E-2,2.0149999999999998E-2,-6.0449999999999997E-2,-7.7500000000000034E-3,-9.4549999999999995E-2,-2.0199999999999999E-2,-2.5999999999999999E-3,-3.15E-2,17,129,11,51,387,33,null,null,0.93225806451612903,6.9204152249134951,null,0.47,0.31,0.73,{"$f":"ROUND((1-EXP(AW8*LN(1-(K8/100))))/(K8/100), 2)","v":0.49},{"$f":"ROUND((1-EXP(AX8*LN(1-(K8/100))))/(K8/100), 2)","v":0.33},{"$f":"ROUND((1-EXP(AY8*LN(1-(K8/100))))/(K8/100), 2)","v":0.75},null,"Chronic kidney disease","ACE inhibitors","Placebo","Progression of CKD - occurrence of ESRD (N)",3,"15.5%",5.1666666666666659E-2,"0.61 (0.95 to 0.39)","60 fewer progressions of CKD (occurrence of ESRD) per 1000 people treated for 3 year(s) (from 8 fewer to 95 fewer)","20 fewer progressions of CKD (occurrence of ESRD) per 1000 people treated per year (from 3 fewer to 32 fewer)","Need to treat 17 people for 3 year(s) to prevent one progression of CKD (occurrence of ESRD) (from treating 129 people to prevent one to treating 11 people to prevent one)","Need to treat 51 people for 1 year to prevent one progression of CKD (occurrence of ESRD) (from treating 387 people to prevent one to treating 33 people to prevent one)","Need to treat 17 people for 3 year(s) to prevent one progression of CKD (occurrence of ESRD) (from treating 129 people to prevent one to treating 11 people)","Need to treat 51 people for 1 year to prevent one progression of CKD (occurrence of ESRD) (from treating 387 people to prevent one to treating 33 people)","-6.05% absolute change in risk of progression of CKD (occurrence of ESRD) per 3 year(s) (from -9.46% to -0.78%)","-2.02% absolute change in risk of progressions of CKD (occurrence of ESRD) per year (from -3.15% to -0.26%)","Offer a low-cost renin-angiotensin system antagonist to people with CKD and diabetes and an ACR of 3 mg/mmol or more OR CKD and hypertension and an ACR of 30 mg/mmol or more OR CKD and an ACR of 70 mg/mmol or more (irrespective of hypertension or cardiovascular disease). ","Taken from recommendation 1.6.3 of the NICE guideline on chronic kidney disease in adults.","3 trials, 2 trials in patients with T2DM, 1 trial in patients with T1DM, mean ages ranging from 34.5 to 66"]
["Chronic kidney disease","Angiotensin II receptor blockers","All cause mortality","deaths","death",291,1477,19.7,null,null,18.399999999999999,{"$f":"4*365","v":1460},1.07,0.92,1.24,1.24,0.92,"N",1,{"$f":"IF($F9=\"\", ROUND((#REF!*10)*(1-M9), 0), ROUND(($K9*10)*(1-M9), 0))","v":-13},{"$f":"IF($F9=\"\", ROUND((#REF!*10)*(1-P9), 0), ROUND(($K9*10)*(1-P9), 0))","v":-44},{"$f":"IF($F9=\"\", ROUND((#REF!*10)*(1-Q9), 0), ROUND(($K9*10)*(1-Q9), 0))","v":15},-3,-11,4,0.19688,0.22816,0.16928000000000001,4.922E-2,5.704E-2,4.2320000000000003E-2,1.2880000000000003E-2,4.4160000000000005E-2,-1.4719999999999978E-2,3.2000000000000002E-3,1.0999999999999999E-2,-3.7000000000000002E-3,-78,-23,68,-312,-92,272,null,null,-7.0652173913043528E-2,-76.923076923076877,null,null,null,null,{"$f":"(1-EXP(AW9*LN(1-(K9/100))))/(K9/100)","v":0},{"$f":"(1-EXP(AX9*LN(1-(K9/100))))/(K9/100)","v":0},{"$f":"(1-EXP(AY9*LN(1-(K9/100))))/(K9/100)","v":0},null,"Chronic kidney disease","Angiotensin II receptor blockers","Placebo","All cause mortality (N)",4,"18.4%",4.5999999999999999E-2,"1.07 (1.24 to 0.92)","13 more deaths per 1000 people treated for 4 year(s) (from 44 more to 15 fewer)","3 more deaths per 1000 people treated per year (from 11 more to 4 fewer)","Need to treat 78 people for 4 year(s) to cause one death (from treating 23 people to cause one to treating 68 people to prevent one)","Need to treat 312 people for 1 year to cause one death (from treating 92 people to  cause one to treating 272 people to prevent one)","Need to treat 78 people for 4 year(s) to cause one death (confidence intervals crossed the line of no effect)","Need to treat 312 people for 1 year to cause one death (confidence intervals crossed the line of no effect)","1.29% absolute change in risk of death per 4 year(s) (from -1.47% to 4.42%)","0.32% absolute change in risk of deaths per year (from -0.37% to 1.1%)","Offer a low-cost renin-angiotensin system antagonist to people with CKD and diabetes and an ACR of 3 mg/mmol or more OR CKD and hypertension and an ACR of 30 mg/mmol or more OR CKD and an ACR of 70 mg/mmol or more (irrespective of hypertension or cardiovascular disease). ","Taken from recommendation 1.6.3 of the NICE guideline on chronic kidney disease in adults.","2 trials, 1 in patients with T2DM, 1 in patients with either CVD or diabetes, mean ages ranging from 60 to 69.5"]
["Chronic kidney disease","Angiotensin II receptor blockers","Cardiovascular events","cardiovascular events","cardiovascular event",140,1224,11.44,null,null,16.7,{"$f":"ROUND(3.3*365, 0)","v":1205},0.67,0.55000000000000004,0.82,0.82,0.55000000000000004,"N",0,{"$f":"IF($F10=\"\", ROUND((#REF!*10)*(1-M10), 0), ROUND(($K10*10)*(1-M10), 0))","v":55},{"$f":"IF($F10=\"\", ROUND((#REF!*10)*(1-P10), 0), ROUND(($K10*10)*(1-P10), 0))","v":30},{"$f":"IF($F10=\"\", ROUND((#REF!*10)*(1-Q10), 0), ROUND(($K10*10)*(1-Q10), 0))","v":75},17,9,23,0.11189,0.13693999999999998,9.1850000000000001E-2,3.3891991701244815E-2,4.1479751037344394E-2,2.7821784232365147E-2,-5.5109999999999992E-2,-3.0060000000000003E-2,-7.5149999999999995E-2,-1.67E-2,-9.1000000000000004E-3,-2.2800000000000001E-2,18,33,13,59,109,43,null,null,0.31497005988023952,19.011406844106464,null,null,null,null,{"$f":"(1-EXP(AW10*LN(1-(K10/100))))/(K10/100)","v":0},{"$f":"(1-EXP(AX10*LN(1-(K10/100))))/(K10/100)","v":0},{"$f":"(1-EXP(AY10*LN(1-(K10/100))))/(K10/100)","v":0},null,"Chronic kidney disease","Angiotensin II receptor blockers","Placebo","Cardiovascular events (N)",3.3,"16.7%",5.0585062240663899E-2,"0.67 (0.82 to 0.55)","55 fewer cardiovascular events per 1000 people treated for 3.3 year(s) (from 30 fewer to 75 fewer)","17 fewer cardiovascular events per 1000 people treated per year (from 9 fewer to 23 fewer)","Need to treat 18 people for 3.3 year(s) to prevent one cardiovascular event (from treating 33 people to prevent one to treating 13 people to prevent one)","Need to treat 59 people for 1 year to prevent one cardiovascular event (from treating 109 people to prevent one to treating 43 people to prevent one)","Need to treat 18 people for 3.3 year(s) to prevent one cardiovascular event (from treating 33 people to prevent one to treating 13 people)","Need to treat 59 people for 1 year to prevent one cardiovascular event (from treating 109 people to prevent one to treating 43 people)","-5.51% absolute change in risk of cardiovascular event per 3.3 year(s) (from -7.52% to -3.01%)","-1.67% absolute change in risk of cardiovascular events per year (from -2.28% to -0.91%)","Offer a low-cost renin-angiotensin system antagonist to people with CKD and diabetes and an ACR of 3 mg/mmol or more OR CKD and hypertension and an ACR of 30 mg/mmol or more OR CKD and an ACR of 70 mg/mmol or more (irrespective of hypertension or cardiovascular disease). ","Taken from recommendation 1.6.3 of the NICE guideline on chronic kidney disease in adults.","3 trials, all in patients with T2DM, mean ages ranging from 58 to 60"]
["Chronic kidney disease","Angiotensin II receptor blockers","Progression of CKD - change in eGFR","progressions of CKD (change in eGFR)","progression of CKD (change in eGFR)",null,null,"Not reported",null,null,21.3,{"$f":"ROUND(3.5*365, 0)","v":1278},0.79,0.65,0.96,0.96,0.65,"N",0,{"$f":"IF($K11=\"\", ROUND((#REF!*10)*(1-M11), 0), ROUND(($K11*10)*(1-M11), 0))","v":45},{"$f":"IF($K11=\"\", ROUND((#REF!*10)*(1-P11), 0), ROUND(($K11*10)*(1-P11), 0))","v":9},{"$f":"IF($K11=\"\", ROUND((#REF!*10)*(1-Q11), 0), ROUND(($K11*10)*(1-Q11), 0))","v":75},13,3,21,0.16827000000000003,0.20448,0.13845000000000002,4.8058333333333342E-2,5.8400000000000001E-2,3.9541666666666669E-2,-4.4729999999999992E-2,-8.5200000000000033E-3,-7.4550000000000005E-2,-1.2800000000000001E-2,-2.3999999999999998E-3,-2.1299999999999999E-2,22,117,13,77,410,46,null,null,{"$error":"#VALUE!"},{"$error":"#VALUE!"},null,0.77,0.62,0.96,{"$f":"ROUND((1-EXP(AW11*LN(1-(K11/100))))/(K11/100), 2)","v":0.79},{"$f":"ROUND((1-EXP(AX11*LN(1-(K11/100))))/(K11/100), 2)","v":0.65},{"$f":"ROUND((1-EXP(AY11*LN(1-(K11/100))))/(K11/100), 2)","v":0.96},null,"Chronic kidney disease","Angiotensin II receptor blockers","Placebo","Progression of CKD - change in eGFR (N)",3.5,"21.3%",6.0833333333333336E-2,"0.79 (0.96 to 0.65)","45 fewer progressions of CKD (change in eGFR) per 1000 people treated for 3.5 year(s) (from 9 fewer to 75 fewer)","13 fewer progressions of CKD (change in eGFR) per 1000 people treated per year (from 3 fewer to 21 fewer)","Need to treat 22 people for 3.5 year(s) to prevent one progression of CKD (change in eGFR) (from treating 117 people to prevent one to treating 13 people to prevent one)","Need to treat 77 people for 1 year to prevent one progression of CKD (change in eGFR) (from treating 410 people to prevent one to treating 46 people to prevent one)","Need to treat 22 people for 3.5 year(s) to prevent one progression of CKD (change in eGFR) (from treating 117 people to prevent one to treating 13 people)","Need to treat 77 people for 1 year to prevent one progression of CKD (change in eGFR) (from treating 410 people to prevent one to treating 46 people)","-4.47% absolute change in risk of progression of CKD (change in eGFR) per 3.5 year(s) (from -7.46% to -0.85%)","-1.28% absolute change in risk of progressions of CKD (change in eGFR) per year (from -2.13% to -0.24%)","Offer a low-cost renin-angiotensin system antagonist to people with CKD and diabetes and an ACR of 3 mg/mmol or more OR CKD and hypertension and an ACR of 30 mg/mmol or more OR CKD and an ACR of 70 mg/mmol or more (irrespective of hypertension or cardiovascular disease). ","Taken from recommendation 1.6.3 of the NICE guideline on chronic kidney disease in adults.","3 trials, all in patients with T2DM, mean ages ranging from 35 to 60"]
["Chronic kidney disease","Angiotensin II receptor blockers","Progression of CKD - occurrence of ESRD","progressions of CKD (occurrence of ESRD)","progression of CKD (occurrence of ESRD)",null,null,"Not reported",null,null,26.9,{"$f":"4.2*365","v":1533},0.82,0.71,0.94,0.94,0.71,"N",0,{"$f":"(ROUND(($K12*10)*(1-M12), 0))","v":48},{"$f":"ROUND(($K12*10)*(1-P12), 0)","v":16},{"$f":"ROUND(($K12*10)*(1-Q12), 0)","v":78},{"$f":"ROUND((T12/(L12/365)), 0)","v":11},{"$f":"ROUND((U12/(L12/365)), 0)","v":4},{"$f":"ROUND((V12/(L12/365)), 0)","v":19},0.22057999999999997,0.25285999999999997,0.19098999999999997,5.2519047619047611E-2,6.0204761904761893E-2,4.5473809523809514E-2,-4.8420000000000026E-2,-1.6140000000000009E-2,-7.8010000000000024E-2,-1.15E-2,-3.8E-3,-1.8599999999999998E-2,21,62,13,88,260,55,null,null,{"$error":"#VALUE!"},{"$error":"#VALUE!"},null,0.8,0.68,0.93,{"$f":"ROUND((1-EXP(AW12*LN(1-(K12/100))))/(K12/100), 2)","v":0.82},{"$f":"ROUND((1-EXP(AX12*LN(1-(K12/100))))/(K12/100), 2)","v":0.71},{"$f":"ROUND((1-EXP(AY12*LN(1-(K12/100))))/(K12/100), 2)","v":0.94},null,"Chronic kidney disease","Angiotensin II receptor blockers","Placebo","Progression of CKD - occurrence of ESRD (N)",4.2,"26.9%",6.4047619047619048E-2,"0.82 (0.94 to 0.71)","48 fewer progressions of CKD (occurrence of ESRD) per 1000 people treated for 4.2 year(s) (from 16 fewer to 78 fewer)","11 fewer progressions of CKD (occurrence of ESRD) per 1000 people treated per year (from 4 fewer to 19 fewer)","Need to treat 21 people for 4.2 year(s) to prevent one progression of CKD (occurrence of ESRD) (from treating 62 people to prevent one to treating 13 people to prevent one)","Need to treat 88 people for 1 year to prevent one progression of CKD (occurrence of ESRD) (from treating 260 people to prevent one to treating 55 people to prevent one)","Need to treat 21 people for 4.2 year(s) to prevent one progression of CKD (occurrence of ESRD) (from treating 62 people to prevent one to treating 13 people)","Need to treat 88 people for 1 year to prevent one progression of CKD (occurrence of ESRD) (from treating 260 people to prevent one to treating 55 people)","-4.84% absolute change in risk of progression of CKD (occurrence of ESRD) per 4.2 year(s) (from -7.8% to -1.61%)","-1.15% absolute change in risk of progressions of CKD (occurrence of ESRD) per year (from -1.86% to -0.38%)","Offer a low-cost renin-angiotensin system antagonist to people with CKD and diabetes and an ACR of 3 mg/mmol or more OR CKD and hypertension and an ACR of 30 mg/mmol or more OR CKD and an ACR of 70 mg/mmol or more (irrespective of hypertension or cardiovascular disease). ","Taken from recommendation 1.6.3 of the NICE guideline on chronic kidney disease in adults.","1 trial, in patients with T2DM, mean age 60"]
["Chronic kidney disease","Angiotensin II receptor blockers","Acute kidney injury","acute kidney injuries","acute kidney injury",1,282,{"$f":"ROUND((F13/G13)*100, 2)","v":0.35},null,null,0.4,{"$f":"ROUND(4.5*365, 0)","v":1643},1.01,0.06,16.02,16.02,0.06,"N",1,{"$f":"IF($F13=\"\", ROUND((#REF!*10)*(1-M13), 0), ROUND(($K13*10)*(1-M13), 0))","v":0},{"$f":"IF($F13=\"\", ROUND((#REF!*10)*(1-P13), 0), ROUND(($K13*10)*(1-P13), 0))","v":-60},{"$f":"IF($F13=\"\", ROUND((#REF!*10)*(1-Q13), 0), ROUND(($K13*10)*(1-Q13), 0))","v":4},0,-13,1,4.0400000000000002E-3,6.4079999999999998E-2,2.4000000000000001E-4,8.9750456482045053E-4,1.4235666463785759E-2,5.3317102860620823E-5,4.0000000000000037E-5,6.0080000000000001E-2,-3.7599999999999999E-3,0,1.3299999999999999E-2,-8.0000000000000004E-4,-25000,-17,266,-112534,-77,1197,null,null,0.12500000000000011,1999.9999999999982,null,null,null,null,{"$f":"(1-EXP(AW13*LN(1-(K13/100))))/(K13/100)","v":0},{"$f":"(1-EXP(AX13*LN(1-(K13/100))))/(K13/100)","v":0},{"$f":"(1-EXP(AY13*LN(1-(K13/100))))/(K13/100)","v":0},null,"Chronic kidney disease","Angiotensin II receptor blockers","Placebo","Acute kidney injury (N)",4.5,"0.4%",8.8861838101034706E-4,"1.01 (16.02 to 0.06)","0 more acute kidney injuries per 1000 people treated for 4.5 year(s) (from 60 more to 4 fewer)","0 more acute kidney injuries per 1000 people treated per year (from 13 more to 1 fewer)","Need to treat 25000 people for 4.5 year(s) to cause one acute kidney injury (from treating 17 people to cause one to treating 266 people to prevent one)","Need to treat 112534 people for 1 year to cause one acute kidney injury (from treating 77 people to  cause one to treating 1197 people to prevent one)","Need to treat 25000 people for 4.5 year(s) to cause one acute kidney injury (confidence intervals crossed the line of no effect)","Need to treat 112534 people for 1 year to cause one acute kidney injury (confidence intervals crossed the line of no effect)","0% absolute change in risk of acute kidney injury per 4.5 year(s) (from -0.38% to 6.01%)","0% absolute change in risk of acute kidney injuries per year (from -0.08% to 1.33%)","Offer a low-cost renin-angiotensin system antagonist to people with CKD and diabetes and an ACR of 3 mg/mmol or more OR CKD and hypertension and an ACR of 30 mg/mmol or more OR CKD and an ACR of 70 mg/mmol or more (irrespective of hypertension or cardiovascular disease). ","Taken from recommendation 1.6.3 of the NICE guideline on chronic kidney disease in adults.","1 trial, in patients with T2DM, mean age 59"]
["Chronic kidney disease","Spironolactone","All cause mortality","deaths","death",0,24,0,null,null,7.1,365,0.23,0.01,4.6100000000000003,4.6100000000000003,0.01,"N",1,{"$f":"IF($F14=\"\", ROUND((#REF!*10)*(1-M14), 0), ROUND(($K14*10)*(1-M14), 0))","v":55},{"$f":"IF($F14=\"\", ROUND((#REF!*10)*(1-P14), 0), ROUND(($K14*10)*(1-P14), 0))","v":-256},{"$f":"IF($F14=\"\", ROUND((#REF!*10)*(1-Q14), 0), ROUND(($K14*10)*(1-Q14), 0))","v":70},55,-256,70,1.6330000000000001E-2,0.32730999999999999,7.0999999999999991E-4,1.6330000000000001E-2,0.32730999999999999,7.0999999999999991E-4,-5.4669999999999996E-2,0.25630999999999998,-7.0290000000000005E-2,-5.4699999999999999E-2,0.25629999999999997,-7.0300000000000001E-2,18,-4,14,18,-4,14,null,null,1,14.084507042253522,null,null,null,null,0,0,0,null,"Chronic kidney disease","Spironolactone","Placebo","All cause mortality (N)",1,"7.1%",7.0999999999999994E-2,"0.23 (4.61 to 0.01)","55 fewer deaths per 1000 people treated for 1 year(s) (from 256 more to 70 fewer)","55 fewer deaths per 1000 people treated per year (from 256 more to 70 fewer)","Need to treat 18 people for 1 year(s) to prevent one death (from treating 4 people to cause one to treating 14 people to prevent one)","Need to treat 18 people for 1 year to prevent one death (from treating 4 people to  cause one to treating 14 people to prevent one)","Need to treat 18 people for 1 year(s) to prevent one death (confidence intervals crossed the line of no effect)","Need to treat 18 people for 1 year to prevent one death (confidence intervals crossed the line of no effect)","-5.47% absolute change in risk of death per 1 year(s) (from -7.03% to 25.63%)","-5.47% absolute change in risk of deaths per year (from -7.03% to 25.63%)","Offer a low-cost renin-angiotensin system antagonist to people with CKD and diabetes and an ACR of 3 mg/mmol or more OR CKD and hypertension and an ACR of 30 mg/mmol or more OR CKD and an ACR of 70 mg/mmol or more (irrespective of hypertension or cardiovascular disease). ","Taken from recommendation 1.6.3 of the NICE guideline on chronic kidney disease in adults.","1 trial, patients with T2DM and long term use of ACEi/ARB, mean age 55"]
["Chronic heart failure (in >65)","Beta-blockers","All cause mortality","deaths","death",273,2252,12.12,348,2240,{"$f":"ROUND((I15/J15)*100, 2)","v":15.54},{"$f":"ROUND((((8+27)/2)/12)*365, 0)","v":532},0.78,0.67,0.9,0.9,0.67,"N",0,{"$f":"IF($F15=\"\", ROUND((#REF!*10)*(1-M15), 0), ROUND(($K15*10)*(1-M15), 0))","v":34},{"$f":"IF($F15=\"\", ROUND((#REF!*10)*(1-P15), 0), ROUND(($K15*10)*(1-P15), 0))","v":16},{"$f":"IF($F15=\"\", ROUND((#REF!*10)*(1-Q15), 0), ROUND(($K15*10)*(1-Q15), 0))","v":51},23,11,35,0.121212,0.13985999999999998,0.10411799999999999,8.3162368421052638E-2,9.5956578947368407E-2,7.1434342105263143E-2,-3.4187999999999989E-2,-1.5540000000000003E-2,-5.1281999999999994E-2,-2.35E-2,-1.0699999999999999E-2,-3.5200000000000002E-2,29,64,20,42,93,29,null,null,0.22007722007722008,29.239766081871345,null,null,null,null,0,0,0,null,"Chronic heart failure (in >65)","Beta-blockers","Placebo","All cause mortality (N)",1.5,"348/2240 (15.54%)",0.10661842105263157,"0.78 (0.9 to 0.67)","34 fewer deaths per 1000 people treated for 1.5 year(s) (from 16 fewer to 51 fewer)","23 fewer deaths per 1000 people treated per year (from 11 fewer to 35 fewer)","Need to treat 29 people for 1.5 year(s) to prevent one death (from treating 64 people to prevent one to treating 20 people to prevent one)","Need to treat 42 people for 1 year to prevent one death (from treating 93 people to prevent one to treating 29 people to prevent one)","Need to treat 29 people for 1.5 year(s) to prevent one death (from treating 64 people to prevent one to treating 20 people)","Need to treat 42 people for 1 year to prevent one death (from treating 93 people to prevent one to treating 29 people)","-3.42% absolute change in risk of death per 1.5 year(s) (from -5.13% to -1.55%)","-2.35% absolute change in risk of deaths per year (from -3.52% to -1.07%)","Offer both angiotensin-converting enzyme (ACE) inhibitors and beta-blockers licensed for heart failure to all patients with heart failure due to left ventricular systolic dysfunction. Use clinical judgement when deciding which drug to start first. ","Taken from recommendation 1.2.2.2 of the NICE guideline on  chronic heart failure in adults.","4 trials, ages ranging from at least 65 to at least 71, EF ranging from less than 30% to less than 35%, NYHA ranging from not reported to II to IV"]
["Chronic heart failure (in >65)","Beta-blockers","Sudden death","sudden deaths","sudden death",86,2057,4.18,142,2053,6.92,{"$f":"ROUND((((21+24)/2)/12)*365, 0)","v":684},0.6,0.47,0.78,0.78,0.47,"N",0,{"$f":"IF($F16=\"\", ROUND((#REF!*10)*(1-M16), 0), ROUND(($K16*10)*(1-M16), 0))","v":28},{"$f":"IF($F16=\"\", ROUND((#REF!*10)*(1-P16), 0), ROUND(($K16*10)*(1-P16), 0))","v":15},{"$f":"IF($F16=\"\", ROUND((#REF!*10)*(1-Q16), 0), ROUND(($K16*10)*(1-Q16), 0))","v":37},15,8,20,4.1520000000000001E-2,5.3975999999999996E-2,3.2523999999999997E-2,2.2156140350877193E-2,2.8802982456140349E-2,1.73556432748538E-2,-2.7679999999999996E-2,-1.5224000000000001E-2,-3.6676E-2,-1.4800000000000001E-2,-8.0999999999999996E-3,-1.9599999999999999E-2,36,66,27,67,124,51,null,null,0.39595375722543358,36.496350364963497,null,null,null,null,0,0,0,null,"Chronic heart failure (in >65)","Beta-blockers","Placebo","Sudden death (N)",1.9,"142/2053 (6.92%)",3.6926900584795315E-2,"0.6 (0.78 to 0.47)","28 fewer sudden deaths per 1000 people treated for 1.9 year(s) (from 15 fewer to 37 fewer)","15 fewer sudden deaths per 1000 people treated per year (from 8 fewer to 20 fewer)","Need to treat 36 people for 1.9 year(s) to prevent one sudden death (from treating 66 people to prevent one to treating 27 people to prevent one)","Need to treat 67 people for 1 year to prevent one sudden death (from treating 124 people to prevent one to treating 51 people to prevent one)","Need to treat 36 people for 1.9 year(s) to prevent one sudden death (from treating 66 people to prevent one to treating 27 people)","Need to treat 67 people for 1 year to prevent one sudden death (from treating 124 people to prevent one to treating 51 people)","-2.77% absolute change in risk of sudden death per 1.9 year(s) (from -3.67% to -1.52%)","-1.48% absolute change in risk of sudden deaths per year (from -1.96% to -0.81%)","Offer both angiotensin-converting enzyme (ACE) inhibitors and beta-blockers licensed for heart failure to all patients with heart failure due to left ventricular systolic dysfunction. Use clinical judgement when deciding which drug to start first. ","Taken from recommendation 1.2.2.2 of the NICE guideline on  chronic heart failure in adults.","2 trials, ages ranging from at least 65 to at least 70, EF ranging from less than 30% to less than 35%, NYHA ranging from not reported to II to IV"]
["Chronic heart failure (in >65)","Beta-blockers","All cause hospitalisation","hospitalisations","hospitalisation",729,2118,34.42,763,2114,36.090000000000003,{"$f":"ROUND((((21+27)/2)/12)*365, 0)","v":730},0.95,0.88,1.03,1.03,0.88,"N",1,{"$f":"IF($F17=\"\", ROUND((#REF!*10)*(1-M17), 0), ROUND(($K17*10)*(1-M17), 0))","v":18},{"$f":"IF($F17=\"\", ROUND((#REF!*10)*(1-P17), 0), ROUND(($K17*10)*(1-P17), 0))","v":-11},{"$f":"IF($F17=\"\", ROUND((#REF!*10)*(1-Q17), 0), ROUND(($K17*10)*(1-Q17), 0))","v":43},9,-6,22,0.34285499999999997,0.37172700000000009,0.31759200000000004,0.17142749999999998,0.18586350000000004,0.15879600000000002,-1.8045000000000044E-2,1.0827000000000026E-2,-4.3307999999999999E-2,-8.9999999999999993E-3,5.4000000000000003E-3,-2.1700000000000001E-2,55,-92,23,110,-184,46,null,null,4.6273205874203423E-2,59.880239520958021,null,null,null,null,0,0,0,null,"Chronic heart failure (in >65)","Beta-blockers","Placebo","All cause hospitalisation (N)",2,"763/2114 (36.09%)",0.18045000000000003,"0.95 (1.03 to 0.88)","18 fewer hospitalisations per 1000 people treated for 2 year(s) (from 11 more to 43 fewer)","9 fewer hospitalisations per 1000 people treated per year (from 6 more to 22 fewer)","Need to treat 55 people for 2 year(s) to prevent one hospitalisation (from treating 92 people to cause one to treating 23 people to prevent one)","Need to treat 110 people for 1 year to prevent one hospitalisation (from treating 184 people to  cause one to treating 46 people to prevent one)","Need to treat 55 people for 2 year(s) to prevent one hospitalisation (confidence intervals crossed the line of no effect)","Need to treat 110 people for 1 year to prevent one hospitalisation (confidence intervals crossed the line of no effect)","-1.8% absolute change in risk of hospitalisation per 2 year(s) (from -4.33% to 1.08%)","-0.9% absolute change in risk of hospitalisations per year (from -2.17% to 0.54%)","Offer both angiotensin-converting enzyme (ACE) inhibitors and beta-blockers licensed for heart failure to all patients with heart failure due to left ventricular systolic dysfunction. Use clinical judgement when deciding which drug to start first. ","Taken from recommendation 1.2.2.2 of the NICE guideline on  chronic heart failure in adults.","3 trials, ages ranging from at least 65 to at least 71, EF ranging from less than 30% to less than 35%, NYHA ranging from not reported to II to IV"]
["Chronic heart failure (in >65)","Beta-blockers","Number of patients experiencing adverse event","adverse events","adverse event",81,134,60.45,78,126,61.9,{"$f":"ROUND((40/52)*365, 0)","v":281},0.98,0.8,1.19,1.19,0.8,"N",1,{"$f":"IF($F18=\"\", ROUND((#REF!*10)*(1-M18), 0), ROUND(($K18*10)*(1-M18), 0))","v":12},{"$f":"IF($F18=\"\", ROUND((#REF!*10)*(1-P18), 0), ROUND(($K18*10)*(1-P18), 0))","v":-118},{"$f":"IF($F18=\"\", ROUND((#REF!*10)*(1-Q18), 0), ROUND(($K18*10)*(1-Q18), 0))","v":124},16,-153,161,0.60661999999999994,0.73660999999999999,0.49520000000000003,0.78795836298932387,0.95680658362989324,0.64323131672597877,-1.2379999999999995E-2,0.11761000000000003,-0.12379999999999995,-1.61E-2,0.15279999999999999,-0.1608,81,-9,8,62,-7,6,null,null,2.3424878836833533E-2,68.965517241379516,null,null,null,null,0,0,0,null,"Chronic heart failure (in >65)","Beta-blockers","Placebo","Number of patients experiencing adverse event (N)",0.8,"78/126 (61.9%)",0.80403914590747316,"0.98 (1.19 to 0.8)","12 fewer adverse events per 1000 people treated for 0.8 year(s) (from 118 more to 124 fewer)","16 fewer adverse events per 1000 people treated per year (from 153 more to 161 fewer)","Need to treat 81 people for 0.8 year(s) to prevent one adverse event (from treating 9 people to cause one to treating 8 people to prevent one)","Need to treat 62 people for 1 year to prevent one adverse event (from treating 7 people to  cause one to treating 6 people to prevent one)","Need to treat 81 people for 0.8 year(s) to prevent one adverse event (confidence intervals crossed the line of no effect)","Need to treat 62 people for 1 year to prevent one adverse event (confidence intervals crossed the line of no effect)","-1.24% absolute change in risk of adverse event per 0.8 year(s) (from -12.38% to 11.76%)","-1.61% absolute change in risk of adverse events per year (from -16.08% to 15.28%)","Offer both angiotensin-converting enzyme (ACE) inhibitors and beta-blockers licensed for heart failure to all patients with heart failure due to left ventricular systolic dysfunction. Use clinical judgement when deciding which drug to start first. ","Taken from recommendation 1.2.2.2 of the NICE guideline on  chronic heart failure in adults.","1 trial, participants aged at least 65, EF less than 35%, NYHA not reported"]
["Angina","Aspirin","All cause mortality","deaths","death",82,1009,8.1300000000000008,106,1026,10.33,{"$f":"ROUND(50*(365/12), 0)","v":1521},0.79,0.6,1.04,1.04,0.6,"N",1,{"$f":"IF($F19=\"\", ROUND((#REF!*10)*(1-M19), 0), ROUND(($K19*10)*(1-M19), 0))","v":22},{"$f":"IF($F19=\"\", ROUND((#REF!*10)*(1-P19), 0), ROUND(($K19*10)*(1-P19), 0))","v":-4},{"$f":"IF($F19=\"\", ROUND((#REF!*10)*(1-Q19), 0), ROUND(($K19*10)*(1-Q19), 0))","v":41},5,-1,10,8.1606999999999999E-2,0.107432,6.1979999999999993E-2,1.9583533859303091E-2,2.5780854700854703E-2,1.4873570019723864E-2,-2.1692999999999997E-2,4.1319999999999977E-3,-4.1320000000000003E-2,-5.1999999999999998E-3,1E-3,-9.9000000000000008E-3,46,-242,24,192,-1008,100,null,null,0.2129719264278799,45.454545454545467,null,null,null,null,0,0,0,null,"Angina","Aspirin","Placebo","All cause mortality (N)",4.2,"106/1026 (10.33%)",2.4789283366206446E-2,"0.79 (1.04 to 0.6)","22 fewer deaths per 1000 people treated for 4.2 year(s) (from 4 more to 41 fewer)","5 fewer deaths per 1000 people treated per year (from 1 more to 10 fewer)","Need to treat 46 people for 4.2 year(s) to prevent one death (from treating 242 people to cause one to treating 24 people to prevent one)","Need to treat 192 people for 1 year to prevent one death (from treating 1008 people to  cause one to treating 100 people to prevent one)","Need to treat 46 people for 4.2 year(s) to prevent one death (confidence intervals crossed the line of no effect)","Need to treat 192 people for 1 year to prevent one death (confidence intervals crossed the line of no effect)","-2.17% absolute change in risk of death per 4.2 year(s) (from -4.13% to 0.41%)","-0.52% absolute change in risk of deaths per year (from -0.99% to 0.1%)","Consider aspirin 75 mg daily for people with stable angina, taking into account the risk of bleeding and comorbidities. ","Taken from recommendation 1.3.5 of the NICE guideline on stable angina.","1 trial, mean age 67, mean duration of angina 4.65 years, excluded those with history of MI"]
["Angina","Aspirin","Fatal MI","fatal MIs","fatal MI",15,1187,1.26,19,1181,1.61,{"$f":"ROUND(55*(365/12), 0)","v":1673},0.79,0.41,1.53,1.53,0.41,"N",1,{"$f":"IF($F20=\"\", ROUND((#REF!*10)*(1-M20), 0), ROUND(($K20*10)*(1-M20), 0))","v":3},{"$f":"IF($F20=\"\", ROUND((#REF!*10)*(1-P20), 0), ROUND(($K20*10)*(1-P20), 0))","v":-9},{"$f":"IF($F20=\"\", ROUND((#REF!*10)*(1-Q20), 0), ROUND(($K20*10)*(1-Q20), 0))","v":9},1,-2,2,1.2719000000000001E-2,2.4633000000000002E-2,6.6010000000000001E-3,2.7749163179916323E-3,5.3742050209205023E-3,1.4401464435146443E-3,-3.3810000000000008E-3,8.5330000000000024E-3,-9.4990000000000005E-3,-6.9999999999999999E-4,1.9E-3,-2.0999999999999999E-3,296,-117,105,1357,-536,481,null,null,0.21739130434782614,285.71428571428567,null,null,null,null,0,0,0,null,"Angina","Aspirin","Placebo","Fatal MI (N)",4.5999999999999996,"19/1181 (1.61%)",3.5125523012552299E-3,"0.79 (1.53 to 0.41)","3 fewer fatal MIs per 1000 people treated for 4.6 year(s) (from 9 more to 9 fewer)","1 fewer fatal MIs per 1000 people treated per year (from 2 more to 2 fewer)","Need to treat 296 people for 4.6 year(s) to prevent one fatal MI (from treating 117 people to cause one to treating 105 people to prevent one)","Need to treat 1357 people for 1 year to prevent one fatal MI (from treating 536 people to  cause one to treating 481 people to prevent one)","Need to treat 296 people for 4.6 year(s) to prevent one fatal MI (confidence intervals crossed the line of no effect)","Need to treat 1357 people for 1 year to prevent one fatal MI (confidence intervals crossed the line of no effect)","-0.34% absolute change in risk of fatal MI per 4.6 year(s) (from -0.95% to 0.85%)","-0.07% absolute change in risk of fatal MIs per year (from -0.21% to 0.19%)","Consider aspirin 75 mg daily for people with stable angina, taking into account the risk of bleeding and comorbidities. ","Taken from recommendation 1.3.5 of the NICE guideline on stable angina.","2 trials, mean ages ranging from 63 to 67, 1 trial with mean duration of angina 4.65 years (no information on other trial in guideline), 1 trial excluded those with history of MI (no information on other trial in guideline)"]
["Angina","Aspirin","Non-fatal MI","non-fatal MIs","non-fatal MI",14,1187,1.18,94,1181,7.96,{"$f":"ROUND(55*(365/12), 0)","v":1673},0.14000000000000001,0.08,0.25,0.25,0.08,"N",0,{"$f":"IF($F21=\"\", ROUND((#REF!*10)*(1-M21), 0), ROUND(($K21*10)*(1-M21), 0))","v":68},{"$f":"IF($F21=\"\", ROUND((#REF!*10)*(1-P21), 0), ROUND(($K21*10)*(1-P21), 0))","v":60},{"$f":"IF($F21=\"\", ROUND((#REF!*10)*(1-Q21), 0), ROUND(($K21*10)*(1-Q21), 0))","v":73},15,13,16,1.1144000000000001E-2,1.9900000000000001E-2,6.3680000000000004E-3,2.4312970711297074E-3,4.3416019127316199E-3,1.3893126120741184E-3,-6.8456000000000003E-2,-5.9699999999999996E-2,-7.3232000000000005E-2,-1.49E-2,-1.2999999999999999E-2,-1.6E-2,15,17,14,69,78,64,null,null,0.85175879396984933,14.749262536873156,null,null,null,null,0,0,0,null,"Angina","Aspirin","Placebo","Non-fatal MI (N)",4.5999999999999996,"94/1181 (7.96%)",1.736640765092648E-2,"0.14 (0.25 to 0.08)","68 fewer non-fatal MIs per 1000 people treated for 4.6 year(s) (from 60 fewer to 73 fewer)","15 fewer non-fatal MIs per 1000 people treated per year (from 13 fewer to 16 fewer)","Need to treat 15 people for 4.6 year(s) to prevent one non-fatal MI (from treating 17 people to prevent one to treating 14 people to prevent one)","Need to treat 69 people for 1 year to prevent one non-fatal MI (from treating 78 people to prevent one to treating 64 people to prevent one)","Need to treat 15 people for 4.6 year(s) to prevent one non-fatal MI (from treating 17 people to prevent one to treating 14 people)","Need to treat 69 people for 1 year to prevent one non-fatal MI (from treating 78 people to prevent one to treating 64 people)","-6.85% absolute change in risk of non-fatal MI per 4.6 year(s) (from -7.32% to -5.97%)","-1.49% absolute change in risk of non-fatal MIs per year (from -1.6% to -1.3%)","Consider aspirin 75 mg daily for people with stable angina, taking into account the risk of bleeding and comorbidities. ","Taken from recommendation 1.3.5 of the NICE guideline on stable angina.","2 trials, mean ages ranging from 63 to 67, 1 trial with mean duration of angina 4.65 years (no information on other trial in guideline), 1 trial excluded those with history of MI (no information on other trial in guideline)"]
["Depression","Antidepressants","Relapse","relapses","relapse",299,1349,22.16,599,1222,49.02,365,0.46,0.4,0.52,0.52,0.4,"N",0,{"$f":"IF($F22=\"\", ROUND((#REF!*10)*(1-M22), 0), ROUND(($K22*10)*(1-M22), 0))","v":265},{"$f":"IF($F22=\"\", ROUND((#REF!*10)*(1-P22), 0), ROUND(($K22*10)*(1-P22), 0))","v":235},{"$f":"IF($F22=\"\", ROUND((#REF!*10)*(1-Q22), 0), ROUND(($K22*10)*(1-Q22), 0))","v":294},265,235,294,0.22549200000000003,0.25490400000000002,0.19608000000000003,0.22549200000000003,0.25490400000000002,0.19608000000000003,-0.264708,-0.23529600000000003,-0.29411999999999999,-0.26469999999999999,-0.23530000000000001,-0.29409999999999997,4,4,3,4,4,3,null,null,0.54793961648306821,3.7230081906180184,null,null,null,null,0,0,0,null,"Depression","Antidepressants","Placebo","Relapse (N)",1,"599/1222 (49.02%)",0.49020000000000002,"0.46 (0.52 to 0.4)","265 fewer relapses per 1000 people treated for 1 year(s) (from 235 fewer to 294 fewer)","265 fewer relapses per 1000 people treated per year (from 235 fewer to 294 fewer)","Need to treat 4 people for 1 year(s) to prevent one relapse (from treating 4 people to prevent one to treating 3 people to prevent one)","Need to treat 4 people for 1 year to prevent one relapse (from treating 4 people to prevent one to treating 3 people to prevent one)","Need to treat 4 people for 1 year(s) to prevent one relapse (from treating 4 people to prevent one to treating 3 people)","Need to treat 4 people for 1 year to prevent one relapse (from treating 4 people to prevent one to treating 3 people)","-26.47% absolute change in risk of relapse per 1 year(s) (from -29.41% to -23.53%)","-26.47% absolute change in risk of relapses per year (from -29.41% to -23.53%)","Do not use antidepressants routinely to treat persistent subthreshold depressive symptoms or mild depression because the risk–benefit ratio is poor, but consider them for people with a past history of moderate or severe depression OR initial presentation of subthreshold depressive symptoms that have been present for a long period (typically at least 2 years) OR subthreshold depressive symptoms or mild depression that persist(s) after other interventions. ","Taken from recommendation 1.4.4.1 of the NICE guideline on depression in adults.","17 trials, 10 trials with <6 months treatment prior to randomisation, 7 trials with >= 6 months treatment prior to randomisation"]
["Schizophrenia","Second generation antipsychotics","Relapse","relapses","relapse",177,912,19.41,246,586,41.98,{"$f":"43*7","v":301},0.41,0.3,0.56999999999999995,0.56999999999999995,0.3,"N",0,{"$f":"IF($F23=\"\", ROUND((#REF!*10)*(1-M23), 0), ROUND(($K23*10)*(1-M23), 0))","v":248},{"$f":"IF($F23=\"\", ROUND((#REF!*10)*(1-P23), 0), ROUND(($K23*10)*(1-P23), 0))","v":181},{"$f":"IF($F23=\"\", ROUND((#REF!*10)*(1-Q23), 0), ROUND(($K23*10)*(1-Q23), 0))","v":294},301,219,357,0.17211799999999997,0.23928599999999997,0.12594,0.20871451827242518,0.29016408637873747,0.15271794019933554,-0.24768200000000001,-0.18051400000000001,-0.29385999999999995,-0.30030000000000001,-0.21890000000000001,-0.35630000000000001,4,6,3,3,5,2,null,null,0.53763696998570742,4.4306601683650868,null,null,null,null,0,0,0,null,"Schizophrenia","Second generation antipsychotics","Placebo","Relapse (N)",0.8,"246/586 (41.98%)",0.50905980066445178,"0.41 (0.57 to 0.3)","248 fewer relapses per 1000 people treated for 0.8 year(s) (from 181 fewer to 294 fewer)","301 fewer relapses per 1000 people treated per year (from 219 fewer to 357 fewer)","Need to treat 4 people for 0.8 year(s) to prevent one relapse (from treating 6 people to prevent one to treating 3 people to prevent one)","Need to treat 3 people for 1 year to prevent one relapse (from treating 5 people to prevent one to treating 2 people to prevent one)","Need to treat 4 people for 0.8 year(s) to prevent one relapse (from treating 6 people to prevent one to treating 3 people)","Need to treat 3 people for 1 year to prevent one relapse (from treating 5 people to prevent one to treating 2 people)","-24.77% absolute change in risk of relapse per 0.8 year(s) (from -29.39% to -18.05%)","-30.03% absolute change in risk of relapses per year (from -35.63% to -21.89%)","For people with first episode psychosis offer oral antipsychotic medication in conjunction with psychological interventions (family intervention and individual CBT). ","Taken from recommendation 1.3.4.1 of the NICE guideline on psychosis and schizophrenia in adults.","8 trials, little information on population available in full guideline, 4 trials in outpatient setting, 1 trial in inpatient setting, 3 trials mixed inpatients and outpatients"]
["Migraine","Beta blockers","Responder rate - patients with >50% reduction in migraine days","responses (defined as >50% reduction in days with migraine)","response (defined as >50% reduction in days with migraine)",43,143,30.07,22,143,15.38,{"$f":"26*7","v":182},1.95,1.24,3.09,1.24,3.09,"P",0,{"$f":"IF($F24=\"\", ROUND((#REF!*10)*(1-M24), 0), ROUND(($K24*10)*(1-M24), 0))","v":-146},{"$f":"IF($F24=\"\", ROUND((#REF!*10)*(1-P24), 0), ROUND(($K24*10)*(1-P24), 0))","v":-37},{"$f":"IF($F24=\"\", ROUND((#REF!*10)*(1-Q24), 0), ROUND(($K24*10)*(1-Q24), 0))","v":-321},-293,-74,-644,0.29991000000000001,0.19071200000000002,0.475242,0.60146785714285711,0.38247186813186818,0.95309521978021972,0.14610999999999999,3.6912E-2,0.32144200000000001,0.29299999999999998,7.3999999999999996E-2,0.64470000000000005,-7,-27,-3,-3,-13,-1,null,null,-0.95513654096228862,-6.8073519400953035,null,null,null,null,0,0,0,null,"Migraine","Beta blockers","Placebo","Responder rate - patients with >50% reduction in migraine days (P)",0.5,"22/143 (15.38%)",0.30844505494505492,"1.95 (1.24 to 3.09)","146 more responses (defined as >50% reduction in days with migraine) per 1000 people treated for 0.5 year(s) (from 37 more to 321 more)","293 more responses (defined as >50% reduction in days with migraine) per 1000 people treated per year (from 74 more to 644 more)","Need to treat 7 people for 0.5 year(s) to achieve one response (defined as >50% reduction in days with migraine) (from treating 27 people to achieve one to treating 3 people to achieve one)","Need to treat 3 people for 1 year to achieve one response (defined as >50% reduction in days with migraine) (from treating 13 people to achieve one to treating to treating 1 people to achieve one)","Need to treat 7 people for 0.5 year(s) to achieve one response (defined as >50% reduction in days with migraine) (from treating 27 people to achieve one to treating 3 people)","Need to treat 3 people for 1 year to achieve one response (defined as >50% reduction in days with migraine) (from treating 13 people to achieve one to treating to treating 1 people)","14.61% absolute change in risk of response (defined as >50% reduction in days with migraine) per 0.5 year(s) (from 32.14% to 3.69%)","29.3% absolute change in risk of responses (defined as >50% reduction in days with migraine) per year (from 64.47% to 7.4%)","Offer topiramate or propranolol for the prophylactic treatment of migraine according to the person’s preference, comorbidities and risk of adverse events. Advise women and girls of childbearing potential that topiramate is associated with a risk of fetal malformations and can impair the effectiveness of hormonal contraceptives. Ensure they are offered suitable contraception if needed. ","Taken from recommendation 1.3.17 of the NICE guideline on headaches in over 12s.","6 trials, mean ages from 14 (1 trial) to ~40 (5 trials), migraine duration ranging from non-specified (2 trials), 6 months (2 trials) to 1 year (2 trials),"]
["Migraine","Topiramate","Responder rate - patients with >50% reduction in migraine days","responses (defined as >50% reduction in days with migraine)","response (defined as >50% reduction in days with migraine)",560,1351,41.45,161,631,25.52,{"$f":"26*7","v":182},1.56,1.27,1.91,1.27,1.91,"P",0,{"$f":"IF($F25=\"\", ROUND((#REF!*10)*(1-M25), 0), ROUND(($K25*10)*(1-M25), 0))","v":-143},{"$f":"IF($F25=\"\", ROUND((#REF!*10)*(1-P25), 0), ROUND(($K25*10)*(1-P25), 0))","v":-69},{"$f":"IF($F25=\"\", ROUND((#REF!*10)*(1-Q25), 0), ROUND(($K25*10)*(1-Q25), 0))","v":-232},-287,-138,-465,0.39811200000000002,0.324104,0.48743199999999992,0.79841142857142866,0.64998879120879116,0.97754219780219764,0.14291200000000001,6.8904000000000035E-2,0.23223199999999994,0.28660000000000002,0.13819999999999999,0.4657,-7,-15,-4,-3,-7,-2,null,null,-0.62421630094043901,-6.2774639045825475,null,null,null,null,0,0,0,null,"Migraine","Topiramate","Placebo","Responder rate - patients with >50% reduction in migraine days (P)",0.5,"161/631 (25.52%)",0.51180219780219782,"1.56 (1.27 to 1.91)","143 more responses (defined as >50% reduction in days with migraine) per 1000 people treated for 0.5 year(s) (from 69 more to 232 more)","287 more responses (defined as >50% reduction in days with migraine) per 1000 people treated per year (from 138 more to 465 more)","Need to treat 7 people for 0.5 year(s) to achieve one response (defined as >50% reduction in days with migraine) (from treating 15 people to achieve one to treating 4 people to achieve one)","Need to treat 3 people for 1 year to achieve one response (defined as >50% reduction in days with migraine) (from treating 7 people to achieve one to treating to treating 2 people to achieve one)","Need to treat 7 people for 0.5 year(s) to achieve one response (defined as >50% reduction in days with migraine) (from treating 15 people to achieve one to treating 4 people)","Need to treat 3 people for 1 year to achieve one response (defined as >50% reduction in days with migraine) (from treating 7 people to achieve one to treating to treating 2 people)","14.29% absolute change in risk of response (defined as >50% reduction in days with migraine) per 0.5 year(s) (from 23.22% to 6.89%)","28.66% absolute change in risk of responses (defined as >50% reduction in days with migraine) per year (from 46.57% to 13.82%)","Offer topiramate or propranolol for the prophylactic treatment of migraine according to the person’s preference, comorbidities and risk of adverse events. Advise women and girls of childbearing potential that topiramate is associated with a risk of fetal malformations and can impair the effectiveness of hormonal contraceptives. Ensure they are offered suitable contraception if needed. ","Taken from recommendation 1.3.17 of the NICE guideline on headaches in over 12s.","1 trial, mean age 41, migraine for at least 1 year"]
["Cardiovascular disease (secondary prevention)","Statins","All cause mortality","deaths","death",null,null,null,null,null,11.4,{"$f":"3.8*365","v":1387},0.87,0.83,0.91,0.91,0.83,"N",0,{"$f":"(ROUND(($K26*10)*(1-M26), 0))","v":15},{"$f":"ROUND(($K26*10)*(1-P26), 0)","v":10},{"$f":"ROUND(($K26*10)*(1-Q26), 0)","v":19},4,3,5,{"$f":"($K26*M26)/100","v":9.9180000000000004E-2},{"$f":"($K26*P26)/100","v":0.10374},{"$f":"($K26*Q26)/100","v":9.4619999999999996E-2},2.6100000000000002E-2,2.7300000000000001E-2,2.4899999999999999E-2,-1.4819999999999993E-2,-1.0259999999999998E-2,-1.9380000000000005E-2,-3.8999999999999998E-3,-2.7000000000000001E-3,-5.1000000000000004E-3,67,97,52,255,369,198,null,null,1,8.7719298245614024,null,null,null,null,0,0,0,null,"Cardiovascular disease (secondary prevention)","Statins","Placebo","All cause mortality (N)",3.8,"11.4%",0.03,"0.87 (0.91 to 0.83)","15 fewer deaths per 1000 people treated for 3.8 year(s) (from 10 fewer to 19 fewer)","4 fewer deaths per 1000 people treated per year (from 3 fewer to 5 fewer)","Need to treat 67 people for 3.8 year(s) to prevent one death (from treating 97 people to prevent one to treating 52 people to prevent one)","Need to treat 255 people for 1 year to prevent one death (from treating 369 people to prevent one to treating 198 people to prevent one)","Need to treat 67 people for 3.8 year(s) to prevent one death (from treating 97 people to prevent one to treating 52 people)","Need to treat 255 people for 1 year to prevent one death (from treating 369 people to prevent one to treating 198 people)","-1.48% absolute change in risk of death per 3.8 year(s) (from -1.94% to -1.03%)","-0.39% absolute change in risk of deaths per year (from -0.51% to -0.27%)","If lifestyle modification is ineffective or inappropriate offer statin treatment after risk assessment (for primary prevention in those with a 10% or greater 10-year risk of developing cardiovascular disease). ","For full details see recommendations 1.3.17 and 1.3.18 of the NICE guideline on cardiovascular disease.","Secondary prevention: Adults with established CVD; median risk (as reported in guideline)"]
["Cardiovascular disease (primary prevention)","Statins","All cause mortality","deaths","death",null,null,null,null,null,4.9000000000000004,{"$f":"3.2*365","v":1168},0.89,0.83,0.96,0.96,0.83,"N",0,{"$f":"(ROUND(($K27*10)*(1-M27), 0))","v":5},{"$f":"ROUND(($K27*10)*(1-P27), 0)","v":2},{"$f":"ROUND(($K27*10)*(1-Q27), 0)","v":8},2,1,3,4.361000000000001E-2,4.7039999999999998E-2,4.0670000000000005E-2,1.3628125000000003E-2,1.47E-2,1.2709375E-2,-5.3899999999999972E-3,-1.960000000000006E-3,-8.3300000000000023E-3,-1.6999999999999999E-3,-5.9999999999999995E-4,-2.5999999999999999E-3,186,510,120,595,1632,384,null,null,1,20.408163265306122,null,null,null,null,0,0,0,null,"Cardiovascular disease (primary prevention)","Statins","Placebo","All cause mortality (N)",3.2,"4.9%",1.53125E-2,"0.89 (0.96 to 0.83)","5 fewer deaths per 1000 people treated for 3.2 year(s) (from 2 fewer to 8 fewer)","2 fewer deaths per 1000 people treated per year (from 1 fewer to 3 fewer)","Need to treat 186 people for 3.2 year(s) to prevent one death (from treating 510 people to prevent one to treating 120 people to prevent one)","Need to treat 595 people for 1 year to prevent one death (from treating 1632 people to prevent one to treating 384 people to prevent one)","Need to treat 186 people for 3.2 year(s) to prevent one death (from treating 510 people to prevent one to treating 120 people)","Need to treat 595 people for 1 year to prevent one death (from treating 1632 people to prevent one to treating 384 people)","-0.54% absolute change in risk of death per 3.2 year(s) (from -0.83% to -0.2%)","-0.17% absolute change in risk of deaths per year (from -0.26% to -0.06%)","Start statin therapy in people with cardiovascular disease… do not delay statin treatment in secondary prevention to manage modifiable risk factors. ","For full details see recommendations 1.3.20 and 1.3.21 of the NICE guideline on cardiovascular disease.","Primary prevention: Adults without established CVD; median risk as reported in guideline"]
["Cardiovascular disease (secondary prevention)","Statins","CV mortality","cardiovascular deaths","cardiovascular death",null,null,null,null,null,7.6,{"$f":"3.8*365","v":1387},0.79,0.75,0.84,0.84,0.75,"N",0,16,12,19,4,3,5,6.0039999999999996E-2,6.3839999999999994E-2,5.6999999999999995E-2,1.5799999999999998E-2,1.6799999999999999E-2,1.4999999999999999E-2,-1.5960000000000002E-2,-1.2160000000000002E-2,-1.9000000000000003E-2,-4.1999999999999997E-3,-3.2000000000000002E-3,-5.0000000000000001E-3,63,82,53,239,312,201,null,null,1,13.157894736842106,null,null,null,null,0,0,0,null,"Cardiovascular disease (secondary prevention)","Statins","Placebo","CV mortality (N)",3.8,"7.6%",1.9999999999999997E-2,"0.79 (0.84 to 0.75)","16 fewer cardiovascular deaths per 1000 people treated for 3.8 year(s) (from 12 fewer to 19 fewer)","4 fewer cardiovascular deaths per 1000 people treated per year (from 3 fewer to 5 fewer)","Need to treat 63 people for 3.8 year(s) to prevent one cardiovascular death (from treating 82 people to prevent one to treating 53 people to prevent one)","Need to treat 239 people for 1 year to prevent one cardiovascular death (from treating 312 people to prevent one to treating 201 people to prevent one)","Need to treat 63 people for 3.8 year(s) to prevent one cardiovascular death (from treating 82 people to prevent one to treating 53 people)","Need to treat 239 people for 1 year to prevent one cardiovascular death (from treating 312 people to prevent one to treating 201 people)","-1.6% absolute change in risk of cardiovascular death per 3.8 year(s) (from -1.9% to -1.22%)","-0.42% absolute change in risk of cardiovascular deaths per year (from -0.5% to -0.32%)","If lifestyle modification is ineffective or inappropriate offer statin treatment after risk assessment (for primary prevention in those with a 10% or greater 10-year risk of developing cardiovascular disease). ","For full details see recommendations 1.3.17 and 1.3.18 of the NICE guideline on cardiovascular disease.","Secondary prevention: Adults with established CVD; median risk (as reported in guideline)"]
["Cardiovascular disease (primary prevention)","Statins","CV mortality","cardiovascular deaths","cardiovascular death",null,null,null,null,null,2,1423,0.9,0.79,1.01,1.01,0.79,"N",1,2,0,4,1,0,1,1.8000000000000002E-2,2.0199999999999999E-2,1.5800000000000002E-2,4.6170063246661992E-3,5.1813070976809558E-3,4.0527055516514409E-3,-1.9999999999999996E-3,2.0000000000000017E-4,-4.1999999999999989E-3,-5.0000000000000001E-4,1E-4,-1.1000000000000001E-3,500,-5000,238,1949,-19493,928,null,null,1,50,null,null,null,null,0,0,0,null,"Cardiovascular disease (primary prevention)","Statins","Placebo","CV mortality (N)",3.9,"2%",5.1300070274068865E-3,"0.9 (1.01 to 0.79)","2 fewer cardiovascular deaths per 1000 people treated for 3.9 year(s) (from 0 more to 4 fewer)","1 fewer cardiovascular deaths per 1000 people treated per year (from 0 more to 1 fewer)","Need to treat 500 people for 3.9 year(s) to prevent one cardiovascular death (from treating 5000 people to cause one to treating 238 people to prevent one)","Need to treat 1949 people for 1 year to prevent one cardiovascular death (from treating 19493 people to  cause one to treating 928 people to prevent one)","Need to treat 500 people for 3.9 year(s) to prevent one cardiovascular death (confidence intervals crossed the line of no effect)","Need to treat 1949 people for 1 year to prevent one cardiovascular death (confidence intervals crossed the line of no effect)","-0.2% absolute change in risk of cardiovascular death per 3.9 year(s) (from -0.42% to 0.02%)","-0.05% absolute change in risk of cardiovascular deaths per year (from -0.11% to 0.01%)","Start statin therapy in people with cardiovascular disease… do not delay statin treatment in secondary prevention to manage modifiable risk factors. ","For full details see recommendations 1.3.17 and 1.3.18 of the NICE guideline on cardiovascular disease.","Primary prevention: Adults without established CVD; median risk as reported in guideline"]
["Cardiovascular disease (secondary prevention)","Statins","Non-fatal MI","non-fatal MIs","non-fatal MI",null,null,null,null,null,7.3,1351,0.7,0.66,0.75,0.75,0.66,"N",0,22,18,25,6,5,7,5.1099999999999993E-2,5.4749999999999993E-2,4.8180000000000008E-2,1.3805699481865283E-2,1.479182087342709E-2,1.3016802368615844E-2,-2.1900000000000003E-2,-1.8250000000000002E-2,-2.4819999999999995E-2,-5.8999999999999999E-3,-4.8999999999999998E-3,-6.7000000000000002E-3,46,55,40,170,204,148,null,null,1,13.698630136986301,null,null,null,null,0,0,0,null,"Cardiovascular disease (secondary prevention)","Statins","Placebo","Non-fatal MI (N)",3.7,"7.3%",1.9722427831236119E-2,"0.7 (0.75 to 0.66)","22 fewer non-fatal MIs per 1000 people treated for 3.7 year(s) (from 18 fewer to 25 fewer)","6 fewer non-fatal MIs per 1000 people treated per year (from 5 fewer to 7 fewer)","Need to treat 46 people for 3.7 year(s) to prevent one non-fatal MI (from treating 55 people to prevent one to treating 40 people to prevent one)","Need to treat 170 people for 1 year to prevent one non-fatal MI (from treating 204 people to prevent one to treating 148 people to prevent one)","Need to treat 46 people for 3.7 year(s) to prevent one non-fatal MI (from treating 55 people to prevent one to treating 40 people)","Need to treat 170 people for 1 year to prevent one non-fatal MI (from treating 204 people to prevent one to treating 148 people)","-2.19% absolute change in risk of non-fatal MI per 3.7 year(s) (from -2.48% to -1.83%)","-0.59% absolute change in risk of non-fatal MIs per year (from -0.67% to -0.49%)","If lifestyle modification is ineffective or inappropriate offer statin treatment after risk assessment (for primary prevention in those with a 10% or greater 10-year risk of developing cardiovascular disease). ","For full details see recommendations 1.3.17 and 1.3.18 of the NICE guideline on cardiovascular disease.","Secondary prevention: Adults with established CVD; median risk (as reported in guideline)"]
["Cardiovascular disease (primary prevention)","Statins","Non-fatal MI","non-fatal MIs","non-fatal MI",null,null,null,null,null,1.8,{"$f":"3.4*365","v":1241},0.61,0.51,0.73,0.73,0.51,"N",0,7,5,9,2,1,3,1.098E-2,1.3140000000000001E-2,9.1800000000000007E-3,3.2294117647058826E-3,3.8647058823529415E-3,2.7000000000000001E-3,-7.0199999999999993E-3,-4.8599999999999997E-3,-8.8199999999999997E-3,-2.0999999999999999E-3,-1.4E-3,-2.5999999999999999E-3,142,206,113,483,700,384,null,null,1,55.555555555555557,null,null,null,null,0,0,0,null,"Cardiovascular disease (primary prevention)","Statins","Placebo","Non-fatal MI (N)",3.4,"1.8%",5.2941176470588233E-3,"0.61 (0.73 to 0.51)","7 fewer non-fatal MIs per 1000 people treated for 3.4 year(s) (from 5 fewer to 9 fewer)","2 fewer non-fatal MIs per 1000 people treated per year (from 1 fewer to 3 fewer)","Need to treat 142 people for 3.4 year(s) to prevent one non-fatal MI (from treating 206 people to prevent one to treating 113 people to prevent one)","Need to treat 483 people for 1 year to prevent one non-fatal MI (from treating 700 people to prevent one to treating 384 people to prevent one)","Need to treat 142 people for 3.4 year(s) to prevent one non-fatal MI (from treating 206 people to prevent one to treating 113 people)","Need to treat 483 people for 1 year to prevent one non-fatal MI (from treating 700 people to prevent one to treating 384 people)","-0.7% absolute change in risk of non-fatal MI per 3.4 year(s) (from -0.88% to -0.49%)","-0.21% absolute change in risk of non-fatal MIs per year (from -0.26% to -0.14%)","Start statin therapy in people with cardiovascular disease… do not delay statin treatment in secondary prevention to manage modifiable risk factors. ","For full details see recommendations 1.3.20 and 1.3.21 of the NICE guideline on cardiovascular disease.","Primary prevention: Adults without established CVD; median risk (as reported in guideline)"]
["Cardiovascular disease (secondary prevention)","Statins","Stroke","strokes","stroke",null,null,null,null,null,5.2,{"$f":"3.2*365","v":1168},0.78,0.72,0.84,0.84,0.72,"N",0,11,8,15,3,3,5,4.0559999999999999E-2,4.3680000000000004E-2,3.7440000000000001E-2,1.2674999999999999E-2,1.3650000000000001E-2,1.17E-2,-1.1440000000000001E-2,-8.3199999999999993E-3,-1.4560000000000003E-2,-3.5999999999999999E-3,-2.5999999999999999E-3,-4.5999999999999999E-3,87,120,69,278,384,221,null,null,1,19.23076923076923,null,null,null,null,0,0,0,null,"Cardiovascular disease (secondary prevention)","Statins","Placebo","Stroke (N)",3.2,"5.2%",1.6250000000000001E-2,"0.78 (0.84 to 0.72)","11 fewer strokes per 1000 people treated for 3.2 year(s) (from 8 fewer to 15 fewer)","3 fewer strokes per 1000 people treated per year (from 3 fewer to 5 fewer)","Need to treat 87 people for 3.2 year(s) to prevent one stroke (from treating 120 people to prevent one to treating 69 people to prevent one)","Need to treat 278 people for 1 year to prevent one stroke (from treating 384 people to prevent one to treating 221 people to prevent one)","Need to treat 87 people for 3.2 year(s) to prevent one stroke (from treating 120 people to prevent one to treating 69 people)","Need to treat 278 people for 1 year to prevent one stroke (from treating 384 people to prevent one to treating 221 people)","-1.14% absolute change in risk of stroke per 3.2 year(s) (from -1.46% to -0.83%)","-0.36% absolute change in risk of strokes per year (from -0.46% to -0.26%)","If lifestyle modification is ineffective or inappropriate offer statin treatment after risk assessment (for primary prevention in those with a 10% or greater 10-year risk of developing cardiovascular disease). ","For full details see recommendations 1.3.17 and 1.3.18 of the NICE guideline on cardiovascular disease.","Secondary prevention: Adults with established CVD; median risk (as reported in guideline)"]
["Cardiovascular disease (primary prevention)","Statins","Stroke","strokes","stroke",null,null,null,null,null,1.8,{"$f":"ROUND(3.7*365, 0)","v":1351},0.79,0.69,0.9,0.9,0.69,"N",0,4,2,6,1,1,2,1.4220000000000002E-2,1.6200000000000003E-2,1.242E-2,3.8418208734270916E-3,4.3767579570688385E-3,3.3555144337527759E-3,-3.7799999999999991E-3,-1.7999999999999993E-3,-5.5800000000000008E-3,-1E-3,-5.0000000000000001E-4,-1.5E-3,265,556,179,981,2058,663,null,null,1,55.555555555555557,null,null,null,null,0,0,0,null,"Cardiovascular disease (primary prevention)","Statins","Placebo","Stroke (N)",3.7,"1.8%",4.8630643967431534E-3,"0.79 (0.9 to 0.69)","4 fewer strokes per 1000 people treated for 3.7 year(s) (from 2 fewer to 6 fewer)","1 fewer strokes per 1000 people treated per year (from 1 fewer to 2 fewer)","Need to treat 265 people for 3.7 year(s) to prevent one stroke (from treating 556 people to prevent one to treating 179 people to prevent one)","Need to treat 981 people for 1 year to prevent one stroke (from treating 2058 people to prevent one to treating 663 people to prevent one)","Need to treat 265 people for 3.7 year(s) to prevent one stroke (from treating 556 people to prevent one to treating 179 people)","Need to treat 981 people for 1 year to prevent one stroke (from treating 2058 people to prevent one to treating 663 people)","-0.38% absolute change in risk of stroke per 3.7 year(s) (from -0.56% to -0.18%)","-0.1% absolute change in risk of strokes per year (from -0.15% to -0.05%)","Start statin therapy in people with cardiovascular disease… do not delay statin treatment in secondary prevention to manage modifiable risk factors. ","For full details see recommendations 1.3.20 and 1.3.21 of the NICE guideline on cardiovascular disease.","Primary prevention: Adults without established CVD; median risk (as reported in guideline)"]
["Hypertension","Antihypertensive drug therapy","All cause mortality","deaths","death",null,null,"Not reported",null,null,7.9,{"$f":"10*365","v":3650},0.88,0.77,1.01,1.01,0.77,"N",1,{"$f":"IF($F34=\"\", ROUND((K34*10)*(1-M34), 0), ROUND(($K34*10)*(1-M34), 0))","v":9},{"$f":"IF($F34=\"\", ROUND((K34*10)*(1-P34), 0), ROUND(($K34*10)*(1-P34), 0))","v":-1},{"$f":"IF($F34=\"\", ROUND((K34*10)*(1-Q34), 0), ROUND(($K34*10)*(1-Q34), 0))","v":18},1,0,2,6.9519999999999998E-2,7.979E-2,6.0830000000000002E-2,6.9519999999999998E-3,7.979E-3,6.0829999999999999E-3,-9.480000000000004E-3,7.8999999999999741E-4,-1.8170000000000002E-2,-8.9999999999999998E-4,1E-4,-1.8E-3,105,-1266,55,1050,-12660,550,null,null,{"$error":"#VALUE!"},{"$error":"#VALUE!"},null,null,null,null,0,0,0,null,"Hypertension","Antihypertensive drug therapy","Placebo","All cause mortality (N)",10,"7.9%",7.9000000000000008E-3,"0.88 (1.01 to 0.77)","9 fewer deaths per 1000 people treated for 10 year(s) (from 1 more to 18 fewer)","1 fewer deaths per 1000 people treated per year (from 0 more to 2 fewer)","Need to treat 105 people for 10 year(s) to prevent one death (from treating 1266 people to cause one to treating 55 people to prevent one)","Need to treat 1050 people for 1 year to prevent one death (from treating 12660 people to  cause one to treating 550 people to prevent one)","Need to treat 105 people for 10 year(s) to prevent one death (confidence intervals crossed the line of no effect)","Need to treat 1050 people for 1 year to prevent one death (confidence intervals crossed the line of no effect)","-0.95% absolute change in risk of death per 10 year(s) (from -1.82% to 0.08%)","-0.09% absolute change in risk of deaths per year (from -0.18% to 0.01%)","Offer antihypertensive drug treatment to people aged under 80 years with stage 1 hypertension who have one or more of target organ damage, established cardiovascular disease, renal disease, diabetes, a 10 year cardiovascular disease risk equivalent to 20% or greater. Offer antihypertensive drug treatment to any people of any age with stage 2 hypertension. ","Taken from recommendations 1.5.1 and 1.5.2 of the NICE guideline on hypertension in adults.  ","Adults with isolated systolic hypertension (SBP 160 - 219 mmHg and DBP less than 90 mmHg); median risk (as reported by guideline)"]
["Hypertension","Antihypertensive drug therapy","Myocardial infarction","MIs","MI",null,null,"Not reported",null,null,4.74,{"$f":"10*365","v":3650},0.75,0.62,0.91,0.91,0.62,"N",0,12,4,18,{"$f":"ROUND((T35/(L35/365)), 0)","v":1},{"$f":"ROUND((U35/(L35/365)), 0)","v":0},{"$f":"ROUND((V35/(L35/365)), 0)","v":2},3.5549999999999998E-2,4.3134000000000006E-2,2.9388000000000001E-2,3.555E-3,4.3134000000000002E-3,2.9388000000000001E-3,{"$f":"((M35*K35)-K35)/100","v":-1.1850000000000001E-2},{"$f":"((P35*K35)-K35)/100","v":-4.2659999999999964E-3},{"$f":"((Q35*K35)-K35)/100","v":-1.8012E-2},-1.1999999999999999E-3,-4.0000000000000002E-4,-1.8E-3,84,234,56,{"$f":"ROUND((AL35*L35)/365, 0)","v":840},{"$f":"ROUND((AM35*L35)/365, 0)","v":2340},{"$f":"ROUND((AN35*L35)/365, 0)","v":560},null,null,{"$f":"(K35-H35)/K35","v":{"$error":"#VALUE!"}},{"$f":"100/(K35*AT35)","v":{"$error":"#VALUE!"}},null,null,null,null,0,0,0,null,{"$f":"A35","v":"Hypertension"},{"$f":"B35","v":"Antihypertensive drug therapy"},"Placebo",{"$f":"CONCATENATE(C35, \" (\", R35, \")\")","v":"Myocardial infarction (N)"},10,"4.74%",4.7400000000000003E-3,"0.75 (0.91 to 0.62)",{"$f":"IFERROR(CONCATENATE(IF(T35>0, T35, -T35), IF(T35>0, CONCATENATE(\" fewer \", D35, \" per 1000 people treated for \"), CONCATENATE(\" more \", D35, \" per 1000 people treated for \")), BH35,\" year(s) \", \"(from \", IF(U35>0, U35,-U35), IF(U35>0, \" fewer to \", \" more to \"), IF(V35>0, V35, -V35), IF(V35>0, \" fewer)\", \" more)\")), \"N/A\")","v":"12 fewer MIs per 1000 people treated for 10 year(s) (from 4 fewer to 18 fewer)"},{"$f":"IFERROR(CONCATENATE(IF(W35>0, W35, -W35), IF(W35>0, CONCATENATE(\" fewer \", D35, \" per 1000 people treated per year\"), CONCATENATE(\" more \", D35, \" per 1000 people treated per year\")), \" (from \", IF(X35>0, X35,-X35), IF(X35>0, \" fewer to \", \" more to \"), IF(Y35>0, Y35, -Y35), IF(Y35>0, \" fewer)\", \" more)\")), \"N/A\")","v":"1 fewer MIs per 1000 people treated per year (from 0 more to 2 fewer)"},{"$f":"IFERROR((IF(R35=\"N\", (CONCATENATE(\"Need to treat \", IF(AL35>0, AL35, -AL35), \" people for \", BH35, \" year(s) to \", IF(AL35>0, CONCATENATE(\"prevent one \", E35), CONCATENATE(\"cause one \", E35)), \" (from treating \", IF(AM35>0, AM35, -AM35), \" people to \", IF(AM35>0, \"prevent one to treating \", \"cause one to treating \"), IF(AN35>0, AN35, -AN35), IF(AN35>0, \" people to prevent one)\", \" people to cause one)\"))), (CONCATENATE(\"Need to treat \", IF(AL35<0, -AL35, AL35), \" people for \", BH35, \" year(s) to \", IF(AL35<0, CONCATENATE(\"achieve one \", E35), CONCATENATE(\"fail to achieve one \", E35)), \" (from treating \", IF(AM35<0, -AM35, AM35), IF(AM35<0, \" people to achieve one \", \" people to fail to achieve one \"),\"to treating \", IF(AN35<0,-AN35, AN35), IF(AN35<0, \" people to achieve one)\", \" people to fail to achieve one)\"))))), \"N/A\")","v":"Need to treat 84 people for 10 year(s) to prevent one MI (from treating 234 people to prevent one to treating 56 people to prevent one)"},{"$f":"IFERROR((IF(R35=\"N\", (CONCATENATE(\"Need to treat \", IF(AO35>0, AO35, -AO35), \" people for 1 year to \", IF(AO35>0, CONCATENATE(\"prevent one \", E35), CONCATENATE(\"cause one \", E35)), \" (from treating \", IF(AP35>0, AP35, -AP35), \" people to \", IF(AP35>0, \"prevent one to treating \", \" cause one to treating \"), IF(AQ35>0, AQ35, -AQ35), IF(AQ35>0, \" people to prevent one)\", \" people to cause one)\"))), (CONCATENATE(\"Need to treat \", IF(AO35<0, -AO35, AO35), IF(AO35<0, CONCATENATE(\" people for 1 year to achieve one \", E35), CONCATENATE(\" people for 1 year to fail to achieve one \", E35)), \" (from treating \", IF(AP35<0, -AP35, AP35), IF(AP35<0, \" people to achieve one to treating \", \" people to fail to achieve one \"),\"to treating \", IF(AQ35<0,-AQ35, AQ35), IF(AQ35<0, \" people to achieve one)\", \" people to fail to achieve one)\"))))), \"N/A\")","v":"Need to treat 840 people for 1 year to prevent one MI (from treating 2340 people to prevent one to treating 560 people to prevent one)"},{"$f":"IFERROR((IF(R35=\"N\", (CONCATENATE(\"Need to treat \", IF(AL35>0, AL35, -AL35), \" people for \", BH35, \" year(s) to \", IF(AL35>0, CONCATENATE(\"prevent one \", E35), CONCATENATE(\"cause one \", E35)), IF(S35=0, CONCATENATE(\" (from treating \", IF(AM35>0, AM35, -AM35), \" people to \", IF(AM35>0, \"prevent one to treating \", \"cause one to treating \"), IF(AN35>0, AN35, -AN35), IF(AN35>0, \" people)\", \" people)\")), \" (confidence intervals crossed the line of no effect)\"))), (CONCATENATE(\"Need to treat \", IF(AL35<0, -AL35, AL35), \" people for \", BH35, \" year(s) to \", IF(AL35<0, CONCATENATE(\"achieve one \", E35), CONCATENATE(\"fail to achieve one \", E35)), IF(S35=0, CONCATENATE(\" (from treating \", IF(AM35<0, -AM35, AM35), IF(AM35<0, \" people to achieve one \", \" people to fail to achieve one \"),\"to treating \", IF(AN35<0,-AN35, AN35), IF(AN35<0, \" people)\", \" people)\")), \" (Confidence intervals crossed the line of no effect)\"))))), \"N/A\")","v":"Need to treat 84 people for 10 year(s) to prevent one MI (from treating 234 people to prevent one to treating 56 people)"},{"$f":"IFERROR((IF(R35=\"N\", (CONCATENATE(\"Need to treat \", IF(AO35>0, AO35, -AO35), \" people for 1 year to \", IF(AO35>0, CONCATENATE(\"prevent one \", E35), CONCATENATE(\"cause one \", E35)), IF(S35=0, CONCATENATE(\" (from treating \", IF(AP35>0, AP35, -AP35), \" people to \", IF(AP35>0, \"prevent one to treating \", \" cause one to treating \"), IF(AQ35>0, AQ35, -AQ35), IF(AQ35>0, \" people)\", \" people)\")), \" (confidence intervals crossed the line of no effect)\"))), (CONCATENATE(\"Need to treat \", IF(AO35<0, -AO35, AO35), IF(AO35<0, CONCATENATE(\" people for 1 year to achieve one \", E35), CONCATENATE(\" people for 1 year to fail to achieve one \", E35)), IF(S35=0, CONCATENATE(\" (from treating \", IF(AP35<0, -AP35, AP35), IF(AP35<0, \" people to achieve one to treating \", \" people to fail to achieve one \"),\"to treating \", IF(AQ35<0,-AQ35, AQ35), IF(AQ35<0, \" people)\", \" people)\")), \" (confidence intervals crossed the line of no effect)\"))))), \"N/A\")","v":"Need to treat 840 people for 1 year to prevent one MI (from treating 2340 people to prevent one to treating 560 people)"},{"$f":"IFERROR(CONCATENATE((100*ROUND($AF35, 4)), \"% absolute change in risk of \", E35, \" per \", BH35, \" year(s) \", \"(from \", 100*ROUND($AH35, 4), \"% to \", (100*ROUND($AG35, 4)), \"%)\"), \"N/A\")","v":"-1.19% absolute change in risk of MI per 10 year(s) (from -1.8% to -0.43%)"},{"$f":"IFERROR(CONCATENATE((100*ROUND($AI35, 4)), \"% absolute change in risk of \", D35, \" per year\",\" (from \", 100*ROUND($AK35, 4), \"% to \", (100*ROUND($AJ35, 4)), \"%)\"), \"N/A\")","v":"-0.12% absolute change in risk of MIs per year (from -0.18% to -0.04%)"},"Offer antihypertensive drug treatment to people aged under 80 years with stage 1 hypertension who have one or more of target organ damage, established cardiovascular disease, renal disease, diabetes, a 10 year cardiovascular disease risk equivalent to 20% or greater. Offer antihypertensive drug treatment to any people of any age with stage 2 hypertension. ","Taken from recommendations 1.5.1 and 1.5.2 of the NICE guideline on hypertension in adults.  ","Adults with isolated systolic hypertension (SBP 160 - 219 mmHg and DBP less than 90 mmHg); median risk (as reported by guideline)"]
["Hypertension","Antihypertensive drug therapy","Stroke","strokes","stroke",null,null,"Not reported",null,null,4.88,3650,0.64,0.52,0.78,0.78,0.52,"N",0,18,11,23,2,1,2,3.1232000000000003E-2,3.8064000000000001E-2,2.5375999999999999E-2,3.1232000000000005E-3,3.8064000000000001E-3,2.5376000000000001E-3,-1.7567999999999997E-2,-1.0735999999999999E-2,-2.3424E-2,-1.8E-3,-1.1000000000000001E-3,-2.3E-3,57,93,43,570,930,430,null,null,{"$error":"#VALUE!"},{"$error":"#VALUE!"},null,null,null,null,0,0,0,null,"Hypertension","Antihypertensive drug therapy","Placebo","Stroke (N)",10,"4.88%",4.8799999999999998E-3,"0.64 (0.78 to 0.52)","18 fewer strokes per 1000 people treated for 10 year(s) (from 11 fewer to 23 fewer)","2 fewer strokes per 1000 people treated per year (from 1 fewer to 2 fewer)","Need to treat 57 people for 10 year(s) to prevent one stroke (from treating 93 people to prevent one to treating 43 people to prevent one)","Need to treat 570 people for 1 year to prevent one stroke (from treating 930 people to prevent one to treating 430 people to prevent one)","Need to treat 57 people for 10 year(s) to prevent one stroke (from treating 93 people to prevent one to treating 43 people)","Need to treat 570 people for 1 year to prevent one stroke (from treating 930 people to prevent one to treating 430 people)","-1.76% absolute change in risk of stroke per 10 year(s) (from -2.34% to -1.07%)","-0.18% absolute change in risk of strokes per year (from -0.23% to -0.11%)","Offer antihypertensive drug treatment to people aged under 80 years with stage 1 hypertension who have one or more of target organ damage, established cardiovascular disease, renal disease, diabetes, a 10 year cardiovascular disease risk equivalent to 20% or greater. Offer antihypertensive drug treatment to any people of any age with stage 2 hypertension. ","Taken from recommendations 1.5.1 and 1.5.2 of the NICE guideline on hypertension in adults.  ","Adults with isolated systolic hypertension (SBP 160 - 219 mmHg and DBP less than 90 mmHg); median risk (as reported by guideline)"]
["Hypertension","Bendroflumethiazide","All cause mortality","deaths","death",null,null,null,null,null,3.6,1789,1,0.81,1.23,1.23,0.81,"N",0,0,-8,7,0,-2,1,{"$f":"($K37*M37)/100","v":3.6000000000000004E-2},{"$f":"($K37*P37)/100","v":4.428E-2},{"$f":"($K37*Q37)/100","v":2.9160000000000005E-2},{"$f":"Z37/($L37/365)","v":7.3448854108440478E-3},{"$f":"AA37/($L37/365)","v":9.0342090553381781E-3},{"$f":"AB37/($L37/365)","v":5.9493571827836794E-3},0,8.2799999999999992E-3,-6.8399999999999971E-3,{"$f":"ROUND(AF37/($L37/365), 4)","v":0},{"$f":"ROUND(AG37/($L37/365), 4)","v":1.6999999999999999E-3},{"$f":"ROUND(AH37/($L37/365), 4)","v":-1.4E-3},{"$error":"#DIV/0!"},-121,146,{"$error":"#DIV/0!"},-593,716,null,null,1,27.777777777777779,null,null,null,null,0,0,0,null,"Hypertension","Bendroflumethiazide","Placebo","All cause mortality (N)",4.9000000000000004,"3.6%",7.3448854108440478E-3,{"$f":"IF(M37=\"\", \"N/A\", CONCATENATE(M37, \" (\", P37, \" to \", Q37, \")\"))","v":"1 (1.23 to 0.81)"},"0 more deaths per 1000 people treated for 4.9 year(s) (from 8 more to 7 fewer)","0 more deaths per 1000 people treated per year (from 2 more to 1 fewer)","N/A","N/A","N/A","N/A","0% absolute change in risk of death per 4.9 year(s) (from -0.68% to 0.83%)","0% absolute change in risk of deaths per year (from -0.14% to 0.17%)","Offer antihypertensive drug treatment to people aged under 80 years with stage 1 hypertension who have one or more of target organ damage, established cardiovascular disease, renal disease, diabetes, a 10 year cardiovascular disease risk equivalent to 20% or greater. Offer antihypertensive drug treatment to any people of any age with stage 2 hypertension. ","Taken from recommendations 1.5.1 and 1.5.2 of the NICE guideline on hypertension in adults.    ","1 trial, mean age of patients 51, mean starting BP 158/90mmHg"]
["Hypertension","Bendroflumethiazide","Coronary heart disease event","coronary heart disease events","coronary heart disease event",null,null,null,null,null,3.4,1789,1,0.8,1.24,1.24,0.8,"N",0,0,-8,7,0,-2,1,3.4000000000000002E-2,4.2160000000000003E-2,2.7200000000000002E-2,6.9368362213527114E-3,8.6016769144773627E-3,5.5494689770821696E-3,0,8.1600000000000023E-3,-6.799999999999997E-3,0,1.6999999999999999E-3,-1.4E-3,{"$error":"#DIV/0!"},-123,147,{"$error":"#DIV/0!"},-603,721,null,null,1,29.411764705882355,null,null,null,null,0,0,0,null,"Hypertension","Bendroflumethiazide","Placebo","Coronary heart disease event (N)",4.9000000000000004,"3.4%",6.9368362213527114E-3,"1 (1.24 to 0.8)","0 more coronary heart disease events per 1000 people treated for 4.9 year(s) (from 8 more to 7 fewer)","0 more coronary heart disease events per 1000 people treated per year (from 2 more to 1 fewer)","N/A","N/A","N/A","N/A","0% absolute change in risk of coronary heart disease event per 4.9 year(s) (from -0.68% to 0.82%)","0% absolute change in risk of coronary heart disease events per year (from -0.14% to 0.17%)","Offer antihypertensive drug treatment to people aged under 80 years with stage 1 hypertension who have one or more of target organ damage, established cardiovascular disease, renal disease, diabetes, a 10 year cardiovascular disease risk equivalent to 20% or greater. Offer antihypertensive drug treatment to any people of any age with stage 2 hypertension. ","Taken from recommendations 1.5.1 and 1.5.2 of the NICE guideline on hypertension in adults.  ","1 trial, mean age of patients 51, mean starting BP 158/90mmHg"]
["Hypertension","Bendroflumethiazide","Stroke","strokes","stroke",null,null,null,null,null,1.6,1789,0.44,0.3,0.63,0.63,0.3,"N",0,9,6,11,2,1,2,7.0400000000000011E-3,1.008E-2,4.7999999999999996E-3,1.4363331470095028E-3,2.0565679150363332E-3,9.793180547792062E-4,-8.9600000000000009E-3,-5.9200000000000008E-3,-1.1200000000000002E-2,-1.8E-3,-1.1999999999999999E-3,-2.3E-3,112,169,89,549,828,436,null,null,1,62.5,null,null,null,null,0,0,0,null,"Hypertension","Bendroflumethiazide","Placebo","Stroke (N)",4.9000000000000004,"1.6%",3.2643935159306879E-3,"0.44 (0.63 to 0.3)","9 fewer strokes per 1000 people treated for 4.9 year(s) (from 6 fewer to 11 fewer)","2 fewer strokes per 1000 people treated per year (from 1 fewer to 2 fewer)","Need to treat 112 people for 4.9 year(s) to prevent one stroke (from treating 169 people to prevent one to treating 89 people to prevent one)","Need to treat 549 people for 1 year to prevent one stroke (from treating 828 people to prevent one to treating 436 people to prevent one)","Need to treat 112 people for 4.9 year(s) to prevent one stroke (from treating 169 people to prevent one to treating 89 people)","Need to treat 549 people for 1 year to prevent one stroke (from treating 828 people to prevent one to treating 436 people)","-0.9% absolute change in risk of stroke per 4.9 year(s) (from -1.12% to -0.59%)","-0.18% absolute change in risk of strokes per year (from -0.23% to -0.12%)","Offer antihypertensive drug treatment to people aged under 80 years with stage 1 hypertension who have one or more of target organ damage, established cardiovascular disease, renal disease, diabetes, a 10 year cardiovascular disease risk equivalent to 20% or greater. Offer antihypertensive drug treatment to any people of any age with stage 2 hypertension. ","Taken from recommendations 1.5.1 and 1.5.2 of the NICE guideline on hypertension in adults.  ","1 trial, mean age of patients 51, mean starting BP 158/90mmHg"]
["Hypertension","Bendroflumethiazide","Cardiovascular events","cardiovascular events","cardiovascular event",null,null,null,null,null,5.0999999999999996,1789,0.78,0.65,0.94,0.94,0.65,"N",0,11,3,18,2,1,4,3.9779999999999996E-2,4.7939999999999997E-2,3.3149999999999999E-2,8.1160983789826703E-3,9.7809390721073225E-3,6.7634153158188928E-3,-1.1219999999999999E-2,-3.0600000000000007E-3,-1.7849999999999998E-2,-2.3E-3,-5.9999999999999995E-4,-3.5999999999999999E-3,89,327,56,436,1603,274,null,null,1,19.607843137254903,null,null,null,null,0,0,0,null,"Hypertension","Bendroflumethiazide","Placebo","Cardiovascular events (N)",4.9000000000000004,"5.1%",1.0405254332029067E-2,"0.78 (0.94 to 0.65)","11 fewer cardiovascular events per 1000 people treated for 4.9 year(s) (from 3 fewer to 18 fewer)","2 fewer cardiovascular events per 1000 people treated per year (from 1 fewer to 4 fewer)","Need to treat 89 people for 4.9 year(s) to prevent one cardiovascular event (from treating 327 people to prevent one to treating 56 people to prevent one)","Need to treat 436 people for 1 year to prevent one cardiovascular event (from treating 1603 people to prevent one to treating 274 people to prevent one)","Need to treat 89 people for 4.9 year(s) to prevent one cardiovascular event (from treating 327 people to prevent one to treating 56 people)","Need to treat 436 people for 1 year to prevent one cardiovascular event (from treating 1603 people to prevent one to treating 274 people)","-1.12% absolute change in risk of cardiovascular event per 4.9 year(s) (from -1.79% to -0.31%)","-0.23% absolute change in risk of cardiovascular events per year (from -0.36% to -0.06%)","Offer antihypertensive drug treatment to people aged under 80 years with stage 1 hypertension who have one or more of target organ damage, established cardiovascular disease, renal disease, diabetes, a 10 year cardiovascular disease risk equivalent to 20% or greater. Offer antihypertensive drug treatment to any people of any age with stage 2 hypertension. ","Taken from recommendations 1.5.1 and 1.5.2 of the NICE guideline on hypertension in adults.  ","1 trial, mean age of patients 51, mean starting BP 158/90mmHg"]
["Hypertension","Indapamide","All cause mortality","deaths","death",null,null,null,null,null,8.3000000000000007,748,0.86,0.75,0.99,0.99,0.75,"N",0,12,1,21,6,0,10,7.1380000000000013E-2,8.2170000000000007E-2,6.2250000000000007E-2,3.4831149732620324E-2,4.0096323529411768E-2,3.0376002673796795E-2,-1.1619999999999998E-2,-8.3000000000000185E-4,-2.0750000000000001E-2,-5.7000000000000002E-3,-4.0000000000000002E-4,-1.01E-2,86,1205,48,176,2469,98,null,null,1,12.048192771084336,null,null,null,null,0,0,0,null,"Hypertension","Indapamide","Placebo","All cause mortality (N)",2,"8.3%",4.0501336898395725E-2,"0.86 (0.99 to 0.75)","12 fewer deaths per 1000 people treated for 2 year(s) (from 1 fewer to 21 fewer)","6 fewer deaths per 1000 people treated per year (from 0 more to 10 fewer)","Need to treat 86 people for 2 year(s) to prevent one death (from treating 1205 people to prevent one to treating 48 people to prevent one)","Need to treat 176 people for 1 year to prevent one death (from treating 2469 people to prevent one to treating 98 people to prevent one)","Need to treat 86 people for 2 year(s) to prevent one death (from treating 1205 people to prevent one to treating 48 people)","Need to treat 176 people for 1 year to prevent one death (from treating 2469 people to prevent one to treating 98 people)","-1.16% absolute change in risk of death per 2 year(s) (from -2.08% to -0.08%)","-0.57% absolute change in risk of deaths per year (from -1.01% to -0.04%)","Offer antihypertensive drug treatment to people aged under 80 years with stage 1 hypertension who have one or more of target organ damage, established cardiovascular disease, renal disease, diabetes, a 10 year cardiovascular disease risk equivalent to 20% or greater. Offer antihypertensive drug treatment to any people of any age with stage 2 hypertension. ","Taken from recommendations 1.5.1 and 1.5.2 of the NICE guideline on hypertension in adults.  ","2 trials, mean ages ranging from 60 to not reported, starting BP ranging from 154/93 to not reported"]
["Hypertension","Indapamide","Coronary heart disease event","coronary heart disease events","coronary heart disease event",null,null,null,null,null,1.6,748,0.53,0.36,0.77,0.77,0.36,"N",0,8,4,10,4,2,5,8.4800000000000014E-3,1.2320000000000003E-2,5.7599999999999995E-3,4.1379679144385034E-3,6.0117647058823545E-3,2.8106951871657753E-3,-7.5199999999999998E-3,-3.6799999999999988E-3,-1.0240000000000001E-2,-3.7000000000000002E-3,-1.8E-3,-5.0000000000000001E-3,133,272,98,273,557,201,null,null,1,62.5,null,null,null,null,0,0,0,null,"Hypertension","Indapamide","Placebo","Coronary heart disease event (N)",2,"1.6%",7.807486631016043E-3,"0.53 (0.77 to 0.36)","8 fewer coronary heart disease events per 1000 people treated for 2 year(s) (from 4 fewer to 10 fewer)","4 fewer coronary heart disease events per 1000 people treated per year (from 2 fewer to 5 fewer)","Need to treat 133 people for 2 year(s) to prevent one coronary heart disease event (from treating 272 people to prevent one to treating 98 people to prevent one)","Need to treat 273 people for 1 year to prevent one coronary heart disease event (from treating 557 people to prevent one to treating 201 people to prevent one)","Need to treat 133 people for 2 year(s) to prevent one coronary heart disease event (from treating 272 people to prevent one to treating 98 people)","Need to treat 273 people for 1 year to prevent one coronary heart disease event (from treating 557 people to prevent one to treating 201 people)","-0.75% absolute change in risk of coronary heart disease event per 2 year(s) (from -1.02% to -0.37%)","-0.37% absolute change in risk of coronary heart disease events per year (from -0.5% to -0.18%)","Offer antihypertensive drug treatment to people aged under 80 years with stage 1 hypertension who have one or more of target organ damage, established cardiovascular disease, renal disease, diabetes, a 10 year cardiovascular disease risk equivalent to 20% or greater. Offer antihypertensive drug treatment to any people of any age with stage 2 hypertension. ","Taken from recommendations 1.5.1 and 1.5.2 of the NICE guideline on hypertension in adults.  ","2 trials, mean ages ranging from 60 to not reported, starting BP ranging from 154/93 to not reported"]
["Hypertension","Indapamide","Stroke","strokes","stroke",null,null,null,null,null,6,748,0.73,0.62,0.87,0.87,0.62,"N",0,16,8,23,8,4,11,4.3799999999999999E-2,5.2199999999999996E-2,3.7199999999999997E-2,2.1372994652406416E-2,2.5471925133689836E-2,1.8152406417112299E-2,-1.6200000000000003E-2,-7.8000000000000022E-3,-2.2800000000000001E-2,-7.9000000000000008E-3,-3.8E-3,-1.11E-2,62,128,44,127,262,90,null,null,1,16.666666666666668,null,null,null,null,0,0,0,null,"Hypertension","Indapamide","Placebo","Stroke (N)",2,"6%",2.927807486631016E-2,"0.73 (0.87 to 0.62)","16 fewer strokes per 1000 people treated for 2 year(s) (from 8 fewer to 23 fewer)","8 fewer strokes per 1000 people treated per year (from 4 fewer to 11 fewer)","Need to treat 62 people for 2 year(s) to prevent one stroke (from treating 128 people to prevent one to treating 44 people to prevent one)","Need to treat 127 people for 1 year to prevent one stroke (from treating 262 people to prevent one to treating 90 people to prevent one)","Need to treat 62 people for 2 year(s) to prevent one stroke (from treating 128 people to prevent one to treating 44 people)","Need to treat 127 people for 1 year to prevent one stroke (from treating 262 people to prevent one to treating 90 people)","-1.62% absolute change in risk of stroke per 2 year(s) (from -2.28% to -0.78%)","-0.79% absolute change in risk of strokes per year (from -1.11% to -0.38%)","Offer antihypertensive drug treatment to people aged under 80 years with stage 1 hypertension who have one or more of target organ damage, established cardiovascular disease, renal disease, diabetes, a 10 year cardiovascular disease risk equivalent to 20% or greater. Offer antihypertensive drug treatment to any people of any age with stage 2 hypertension. ","Taken from recommendations 1.5.1 and 1.5.2 of the NICE guideline on hypertension in adults.  ","2 trials, mean ages ranging from 60 to not reported, starting BP ranging from 154/93 to not reported"]
["Hypertension","Indapamide","Cardiovascular events","cardiovascular events","cardiovascular event",null,null,null,null,null,5.5,748,0.77,0.64,0.93,0.93,0.64,"N",0,13,4,20,6,2,10,4.2350000000000006E-2,5.1150000000000001E-2,3.5200000000000002E-2,2.0665441176470591E-2,2.4959558823529411E-2,1.7176470588235297E-2,-1.2649999999999996E-2,-3.849999999999998E-3,-1.9799999999999998E-2,-6.1999999999999998E-3,-1.9E-3,-9.7000000000000003E-3,79,260,51,162,533,105,null,null,1,18.181818181818183,null,null,null,null,0,0,0,null,"Hypertension","Indapamide","Placebo","Cardiovascular events (N)",2,"5.5%",2.6838235294117649E-2,"0.77 (0.93 to 0.64)","13 fewer cardiovascular events per 1000 people treated for 2 year(s) (from 4 fewer to 20 fewer)","6 fewer cardiovascular events per 1000 people treated per year (from 2 fewer to 10 fewer)","Need to treat 79 people for 2 year(s) to prevent one cardiovascular event (from treating 260 people to prevent one to treating 51 people to prevent one)","Need to treat 162 people for 1 year to prevent one cardiovascular event (from treating 533 people to prevent one to treating 105 people to prevent one)","Need to treat 79 people for 2 year(s) to prevent one cardiovascular event (from treating 260 people to prevent one to treating 51 people)","Need to treat 162 people for 1 year to prevent one cardiovascular event (from treating 533 people to prevent one to treating 105 people)","-1.27% absolute change in risk of cardiovascular event per 2 year(s) (from -1.98% to -0.39%)","-0.62% absolute change in risk of cardiovascular events per year (from -0.97% to -0.19%)","Offer antihypertensive drug treatment to people aged under 80 years with stage 1 hypertension who have one or more of target organ damage, established cardiovascular disease, renal disease, diabetes, a 10 year cardiovascular disease risk equivalent to 20% or greater. Offer antihypertensive drug treatment to any people of any age with stage 2 hypertension. ","Taken from recommendations 1.5.1 and 1.5.2 of the NICE guideline on hypertension in adults.  ","2 trials, mean ages ranging from 60 to not reported, starting BP ranging from 154/93 to not reported"]
["Hypertension","Indapamide","Quality of life - no limitations in daily activities","patients with no limitation of ADLs","patient with no limitation of ADLs",null,null,null,null,null,71.5,{"$f":"365*2","v":730},1.04,1.01,1.07,1.01,1.07,"P",0,-29,-7,-50,-15,-4,-25,0.74360000000000004,0.72215000000000007,0.76505000000000012,0.37180000000000002,0.36107500000000003,0.38252500000000006,2.8599999999999993E-2,7.1500000000000339E-3,5.0050000000000094E-2,1.43E-2,3.5999999999999999E-3,2.5000000000000001E-2,-35,-140,-20,-70,-280,-40,null,null,1,1.3986013986013985,null,null,null,null,0,0,0,null,"Hypertension","Indapamide","Placebo","Quality of life - no limitations in daily activities (P)",{"$f":"IF(L45/365=0, \"N/A\", ROUND(L45/365, 1))","v":2},{"$f":"IFERROR(IF(I45<>\"\", CONCATENATE(I45, \"/\", J45, \" (\", K45, \"%)\"), CONCATENATE(K45, \"%\")), \"N/A\")","v":"71.5%"},{"$f":"IFERROR((K45*(365/L45))/100, \"N/A\")","v":0.35749999999999998},"1.04 (1.01 to 1.07)","29 more patients with no limitation of ADLs per 1000 people treated for 2 year(s) (from 7 more to 50 more)","15 more patients with no limitation of ADLs per 1000 people treated per year (from 4 more to 25 more)","Need to treat 35 people for 2 year(s) to achieve one patient with no limitation of ADLs (from treating 140 people to achieve one to treating 20 people to achieve one)","Need to treat 70 people for 1 year to achieve one patient with no limitation of ADLs (from treating 280 people to achieve one to treating to treating 40 people to achieve one)","Need to treat 35 people for 2 year(s) to achieve one patient with no limitation of ADLs (from treating 140 people to achieve one to treating 20 people)","Need to treat 70 people for 1 year to achieve one patient with no limitation of ADLs (from treating 280 people to achieve one to treating to treating 40 people)","2.86% absolute change in risk of patient with no limitation of ADLs per 2 year(s) (from 5.01% to 0.72%)","1.43% absolute change in risk of patients with no limitation of ADLs per year (from 2.5% to 0.36%)","Offer antihypertensive drug treatment to people aged under 80 years with stage 1 hypertension who have one or more of target organ damage, established cardiovascular disease, renal disease, diabetes, a 10 year cardiovascular disease risk equivalent to 20% or greater. Offer antihypertensive drug treatment to any people of any age with stage 2 hypertension. ","Taken from recommendations 1.5.1 and 1.5.2 of the NICE guideline on hypertension in adults.  ","1 trial, mean age 60, mean starting BP 154/93 "]
["Hypertension","Chlorthalidone","All cause mortality","deaths","death",null,null,null,null,null,1,{"$f":"365*2","v":730},0.87,0.73,1.04,1.04,0.73,"N",1,1,0,3,1,0,2,8.6999999999999994E-3,1.04E-2,7.3000000000000001E-3,4.3499999999999997E-3,5.1999999999999998E-3,3.65E-3,-1.2999999999999999E-3,4.0000000000000034E-4,-2.7000000000000001E-3,-6.9999999999999999E-4,2.0000000000000001E-4,-1.4E-3,769,-2500,370,1538,-5000,740,null,null,1,100,null,null,null,null,0,0,0,null,"Hypertension","Chlorthalidone","Placebo","All cause mortality (N)",2,"1%",5.0000000000000001E-3,"0.87 (1.04 to 0.73)","1 fewer deaths per 1000 people treated for 2 year(s) (from 0 more to 3 fewer)","1 fewer deaths per 1000 people treated per year (from 0 more to 2 fewer)","Need to treat 769 people for 2 year(s) to prevent one death (from treating 2500 people to cause one to treating 370 people to prevent one)","Need to treat 1538 people for 1 year to prevent one death (from treating 5000 people to  cause one to treating 740 people to prevent one)","Need to treat 769 people for 2 year(s) to prevent one death (confidence intervals crossed the line of no effect)","Need to treat 1538 people for 1 year to prevent one death (confidence intervals crossed the line of no effect)","-0.13% absolute change in risk of death per 2 year(s) (from -0.27% to 0.04%)","-0.07% absolute change in risk of deaths per year (from -0.14% to 0.02%)","Offer antihypertensive drug treatment to people aged under 80 years with stage 1 hypertension who have one or more of target organ damage, established cardiovascular disease, renal disease, diabetes, a 10 year cardiovascular disease risk equivalent to 20% or greater. Offer antihypertensive drug treatment to any people of any age with stage 2 hypertension. ","Taken from recommendations 1.5.1 and 1.5.2 of the NICE guideline on hypertension in adults.  ","3 trials, mean ages ranging from 38 to 72, mean starting BP ranging from not reported to 172/75"]
["Hypertension","Chlorthalidone","Coronary heart disease event","coronary heart disease events","coronary heart disease event",null,null,null,null,null,1.6,{"$f":"365*2","v":730},1.98,0.86,4.53,4.53,0.86,"N",1,-16,-56,2,-8,-28,1,3.168E-2,7.2480000000000017E-2,1.3760000000000001E-2,1.584E-2,3.6240000000000008E-2,6.8800000000000007E-3,1.5679999999999999E-2,5.6480000000000016E-2,-2.2399999999999998E-3,7.7999999999999996E-3,2.8199999999999999E-2,-1.1000000000000001E-3,-64,-18,446,-128,-36,892,null,null,1,62.5,null,null,null,null,0,0,0,null,"Hypertension","Chlorthalidone","Placebo","Coronary heart disease event (N)",2,"1.6%",8.0000000000000002E-3,"1.98 (4.53 to 0.86)","16 more coronary heart disease events per 1000 people treated for 2 year(s) (from 56 more to 2 fewer)","8 more coronary heart disease events per 1000 people treated per year (from 28 more to 1 fewer)","Need to treat 64 people for 2 year(s) to cause one coronary heart disease event (from treating 18 people to cause one to treating 446 people to prevent one)","Need to treat 128 people for 1 year to cause one coronary heart disease event (from treating 36 people to  cause one to treating 892 people to prevent one)","Need to treat 64 people for 2 year(s) to cause one coronary heart disease event (confidence intervals crossed the line of no effect)","Need to treat 128 people for 1 year to cause one coronary heart disease event (confidence intervals crossed the line of no effect)","1.57% absolute change in risk of coronary heart disease event per 2 year(s) (from -0.22% to 5.65%)","0.78% absolute change in risk of coronary heart disease events per year (from -0.11% to 2.82%)","Offer antihypertensive drug treatment to people aged under 80 years with stage 1 hypertension who have one or more of target organ damage, established cardiovascular disease, renal disease, diabetes, a 10 year cardiovascular disease risk equivalent to 20% or greater. Offer antihypertensive drug treatment to any people of any age with stage 2 hypertension. ","Taken from recommendations 1.5.1 and 1.5.2 of the NICE guideline on hypertension in adults.  ","3 trials, mean ages ranging from 38 to 72, mean starting BP ranging from not reported to 172/75"]
["Hypertension","Chlorthalidone","Stroke","strokes","stroke",null,null,null,null,null,6.7,{"$f":"365*2","v":730},0.64,0.5,0.81,0.81,0.5,"N",0,24,13,34,12,7,17,4.2880000000000001E-2,5.4270000000000006E-2,3.3500000000000002E-2,2.1440000000000001E-2,2.7135000000000003E-2,1.6750000000000001E-2,-2.4119999999999999E-2,-1.2729999999999997E-2,-3.3500000000000002E-2,-1.21E-2,-6.4000000000000003E-3,-1.6799999999999999E-2,41,79,30,82,158,60,null,null,1,14.925373134328359,null,null,null,null,0,0,0,null,"Hypertension","Chlorthalidone","Placebo","Stroke (N)",2,"6.7%",3.3500000000000002E-2,"0.64 (0.81 to 0.5)","24 fewer strokes per 1000 people treated for 2 year(s) (from 13 fewer to 34 fewer)","12 fewer strokes per 1000 people treated per year (from 7 fewer to 17 fewer)","Need to treat 41 people for 2 year(s) to prevent one stroke (from treating 79 people to prevent one to treating 30 people to prevent one)","Need to treat 82 people for 1 year to prevent one stroke (from treating 158 people to prevent one to treating 60 people to prevent one)","Need to treat 41 people for 2 year(s) to prevent one stroke (from treating 79 people to prevent one to treating 30 people)","Need to treat 82 people for 1 year to prevent one stroke (from treating 158 people to prevent one to treating 60 people)","-2.41% absolute change in risk of stroke per 2 year(s) (from -3.35% to -1.27%)","-1.21% absolute change in risk of strokes per year (from -1.68% to -0.64%)","Offer antihypertensive drug treatment to people aged under 80 years with stage 1 hypertension who have one or more of target organ damage, established cardiovascular disease, renal disease, diabetes, a 10 year cardiovascular disease risk equivalent to 20% or greater. Offer antihypertensive drug treatment to any people of any age with stage 2 hypertension. ","Taken from recommendations 1.5.1 and 1.5.2 of the NICE guideline on hypertension in adults.  ","2 trials, mean ages ranging from 38 to 72, mean starting BP ranging from not reported to 170/77"]
["Hypertension","ACE inhibitors","Mortality","deaths","death",null,null,null,null,null,{"$f":"2.7*3.9","v":10.530000000000001},1424,0.96,0.83,1.1200000000000001,{"$f":"IF(R49=\"N\", O49, N49)","v":1.1200000000000001},{"$f":"IF(R49=\"N\", N49, O49)","v":0.83},"N",1,{"$f":"IF($F49=\"\", ROUND((K49*10)*(1-M49), 0), ROUND(($K49*10)*(1-M49), 0))","v":4},{"$f":"IF($F49=\"\", ROUND((K49*10)*(1-P49), 0), ROUND(($K49*10)*(1-P49), 0))","v":-13},{"$f":"IF($F49=\"\", ROUND((K49*10)*(1-Q49), 0), ROUND(($K49*10)*(1-Q49), 0))","v":18},{"$f":"ROUND((T49/(L49/365)), 0)","v":1},{"$f":"ROUND((U49/(L49/365)), 0)","v":-3},{"$f":"ROUND((V49/(L49/365)), 0)","v":5},{"$f":"($K49*M49)/100","v":0.10108800000000001},{"$f":"($K49*P49)/100","v":0.11793600000000003},{"$f":"($K49*Q49)/100","v":8.7399000000000004E-2},{"$f":"Z49/($L49/365)","v":2.5910898876404499E-2},{"$f":"AA49/($L49/365)","v":3.0229382022471916E-2},{"$f":"AB49/($L49/365)","v":2.240213132022472E-2},{"$f":"((M49*K49)-K49)/100","v":-4.2120000000000065E-3},{"$f":"((P49*K49)-K49)/100","v":1.263600000000002E-2},{"$f":"((Q49*K49)-K49)/100","v":-1.7901000000000007E-2},{"$f":"ROUND(AF49/($L49/365), 4)","v":-1.1000000000000001E-3},{"$f":"ROUND(AG49/($L49/365), 4)","v":3.2000000000000002E-3},{"$f":"ROUND(AH49/($L49/365), 4)","v":-4.5999999999999999E-3},{"$f":"ROUND(1/-AF49, 0)","v":237},{"$f":"ROUND(1/-AG49, 0)","v":-79},{"$f":"ROUND(1/-AH49, 0)","v":56},{"$f":"ROUND((AL49*L49)/365, 0)","v":925},{"$f":"ROUND((AM49*L49)/365, 0)","v":-308},{"$f":"ROUND((AN49*L49)/365, 0)","v":218},null,null,{"$f":"(K49-H49)/K49","v":1},{"$f":"100/(K49*AT49)","v":9.4966761633428298},null,null,null,null,{"$f":"(1-EXP(AW49*LN(1-(K49/100))))/(K49/100)","v":0},{"$f":"(1-EXP(AX49*LN(1-(K49/100))))/(K49/100)","v":0},{"$f":"(1-EXP(AY49*LN(1-(K49/100))))/(K49/100)","v":0},null,{"$f":"A49","v":"Hypertension"},{"$f":"B49","v":"ACE inhibitors"},"Placebo",{"$f":"CONCATENATE(C49, \" (\", R49, \")\")","v":"Mortality (N)"},{"$f":"IF(L49/365=0, \"N/A\", ROUND(L49/365, 1))","v":3.9},{"$f":"IFERROR(IF(I49<>\"\", CONCATENATE(I49, \"/\", J49, \" (\", K49, \"%)\"), CONCATENATE(K49, \"%\")), \"N/A\")","v":"10.53%"},{"$f":"IFERROR((K49*(365/L49))/100, \"N/A\")","v":2.6990519662921351E-2},{"$f":"IF(M49=\"\", \"N/A\", CONCATENATE(M49, \" (\", P49, \" to \", Q49, \")\"))","v":"0.96 (1.12 to 0.83)"},{"$f":"IFERROR(CONCATENATE(IF(T49>0, T49, -T49), IF(T49>0, CONCATENATE(\" fewer \", D49, \" per 1000 people treated for \"), CONCATENATE(\" more \", D49, \" per 1000 people treated for \")), BH49,\" year(s) \", \"(from \", IF(U49>0, U49,-U49), IF(U49>0, \" fewer to \", \" more to \"), IF(V49>0, V49, -V49), IF(V49>0, \" fewer)\", \" more)\")), \"N/A\")","v":"4 fewer deaths per 1000 people treated for 3.9 year(s) (from 13 more to 18 fewer)"},{"$f":"IFERROR(CONCATENATE(IF(W49>0, W49, -W49), IF(W49>0, CONCATENATE(\" fewer \", D49, \" per 1000 people treated per year\"), CONCATENATE(\" more \", D49, \" per 1000 people treated per year\")), \" (from \", IF(X49>0, X49,-X49), IF(X49>0, \" fewer to \", \" more to \"), IF(Y49>0, Y49, -Y49), IF(Y49>0, \" fewer)\", \" more)\")), \"N/A\")","v":"1 fewer deaths per 1000 people treated per year (from 3 more to 5 fewer)"},{"$f":"IFERROR((IF(R49=\"N\", (CONCATENATE(\"Need to treat \", IF(AL49>0, AL49, -AL49), \" people for \", BH49, \" year(s) to \", IF(AL49>0, CONCATENATE(\"prevent one \", E49), CONCATENATE(\"cause one \", E49)), \" (from treating \", IF(AM49>0, AM49, -AM49), \" people to \", IF(AM49>0, \"prevent one to treating \", \"cause one to treating \"), IF(AN49>0, AN49, -AN49), IF(AN49>0, \" people to prevent one)\", \" people to cause one)\"))), (CONCATENATE(\"Need to treat \", IF(AL49<0, -AL49, AL49), \" people for \", BH49, \" year(s) to \", IF(AL49<0, CONCATENATE(\"achieve one \", E49), CONCATENATE(\"fail to achieve one \", E49)), \" (from treating \", IF(AM49<0, -AM49, AM49), IF(AM49<0, \" people to achieve one \", \" people to fail to achieve one \"),\"to treating \", IF(AN49<0,-AN49, AN49), IF(AN49<0, \" people to achieve one)\", \" people to fail to achieve one)\"))))), \"N/A\")","v":"Need to treat 237 people for 3.9 year(s) to prevent one death (from treating 79 people to cause one to treating 56 people to prevent one)"},{"$f":"IFERROR((IF(R49=\"N\", (CONCATENATE(\"Need to treat \", IF(AO49>0, AO49, -AO49), \" people for 1 year to \", IF(AO49>0, CONCATENATE(\"prevent one \", E49), CONCATENATE(\"cause one \", E49)), \" (from treating \", IF(AP49>0, AP49, -AP49), \" people to \", IF(AP49>0, \"prevent one to treating \", \" cause one to treating \"), IF(AQ49>0, AQ49, -AQ49), IF(AQ49>0, \" people to prevent one)\", \" people to cause one)\"))), (CONCATENATE(\"Need to treat \", IF(AO49<0, -AO49, AO49), IF(AO49<0, CONCATENATE(\" people for 1 year to achieve one \", E49), CONCATENATE(\" people for 1 year to fail to achieve one \", E49)), \" (from treating \", IF(AP49<0, -AP49, AP49), IF(AP49<0, \" people to achieve one to treating \", \" people to fail to achieve one \"),\"to treating \", IF(AQ49<0,-AQ49, AQ49), IF(AQ49<0, \" people to achieve one)\", \" people to fail to achieve one)\"))))), \"N/A\")","v":"Need to treat 925 people for 1 year to prevent one death (from treating 308 people to  cause one to treating 218 people to prevent one)"},{"$f":"IFERROR((IF(R49=\"N\", (CONCATENATE(\"Need to treat \", IF(AL49>0, AL49, -AL49), \" people for \", BH49, \" year(s) to \", IF(AL49>0, CONCATENATE(\"prevent one \", E49), CONCATENATE(\"cause one \", E49)), IF(S49=0, CONCATENATE(\" (from treating \", IF(AM49>0, AM49, -AM49), \" people to \", IF(AM49>0, \"prevent one to treating \", \"cause one to treating \"), IF(AN49>0, AN49, -AN49), IF(AN49>0, \" people)\", \" people)\")), \" (confidence intervals crossed the line of no effect)\"))), (CONCATENATE(\"Need to treat \", IF(AL49<0, -AL49, AL49), \" people for \", BH49, \" year(s) to \", IF(AL49<0, CONCATENATE(\"achieve one \", E49), CONCATENATE(\"fail to achieve one \", E49)), IF(S49=0, CONCATENATE(\" (from treating \", IF(AM49<0, -AM49, AM49), IF(AM49<0, \" people to achieve one \", \" people to fail to achieve one \"),\"to treating \", IF(AN49<0,-AN49, AN49), IF(AN49<0, \" people)\", \" people)\")), \" (Confidence intervals crossed the line of no effect)\"))))), \"N/A\")","v":"Need to treat 237 people for 3.9 year(s) to prevent one death (confidence intervals crossed the line of no effect)"},{"$f":"IFERROR((IF(R49=\"N\", (CONCATENATE(\"Need to treat \", IF(AO49>0, AO49, -AO49), \" people for 1 year to \", IF(AO49>0, CONCATENATE(\"prevent one \", E49), CONCATENATE(\"cause one \", E49)), IF(S49=0, CONCATENATE(\" (from treating \", IF(AP49>0, AP49, -AP49), \" people to \", IF(AP49>0, \"prevent one to treating \", \" cause one to treating \"), IF(AQ49>0, AQ49, -AQ49), IF(AQ49>0, \" people)\", \" people)\")), \" (confidence intervals crossed the line of no effect)\"))), (CONCATENATE(\"Need to treat \", IF(AO49<0, -AO49, AO49), IF(AO49<0, CONCATENATE(\" people for 1 year to achieve one \", E49), CONCATENATE(\" people for 1 year to fail to achieve one \", E49)), IF(S49=0, CONCATENATE(\" (from treating \", IF(AP49<0, -AP49, AP49), IF(AP49<0, \" people to achieve one to treating \", \" people to fail to achieve one \"),\"to treating \", IF(AQ49<0,-AQ49, AQ49), IF(AQ49<0, \" people)\", \" people)\")), \" (confidence intervals crossed the line of no effect)\"))))), \"N/A\")","v":"Need to treat 925 people for 1 year to prevent one death (confidence intervals crossed the line of no effect)"},{"$f":"IFERROR(CONCATENATE((100*ROUND($AF49, 4)), \"% absolute change in risk of \", E49, \" per \", BH49, \" year(s) \", \"(from \", 100*ROUND($AH49, 4), \"% to \", (100*ROUND($AG49, 4)), \"%)\"), \"N/A\")","v":"-0.42% absolute change in risk of death per 3.9 year(s) (from -1.79% to 1.26%)"},{"$f":"IFERROR(CONCATENATE((100*ROUND($AI49, 4)), \"% absolute change in risk of \", D49, \" per year\",\" (from \", 100*ROUND($AK49, 4), \"% to \", (100*ROUND($AJ49, 4)), \"%)\"), \"N/A\")","v":"-0.11% absolute change in risk of deaths per year (from -0.46% to 0.32%)"},"Offer antihypertensive drug treatment to people aged under 80 years with stage 1 hypertension who have one or more of target organ damage, established cardiovascular disease, renal disease, diabetes, a 10 year cardiovascular disease risk equivalent to 20% or greater. Offer antihypertensive drug treatment to any people of any age with stage 2 hypertension. ","Taken from recommendations 1.5.1 and 1.5.2 of the NICE guideline on hypertension in adults.  ","1 trial, mean age 64, mean starting BP 147/86"]
["Hypertension","Angiotensin II receptor blockers","Mortality","deaths","death",null,null,null,null,null,{"$f":"2.9*3.7","v":10.73},1351,0.97,0.83,1.1399999999999999,1.1399999999999999,0.83,"N",1,3,-15,18,1,-4,5,0.10408099999999999,0.12232199999999999,8.9058999999999985E-2,2.8119589193190228E-2,3.3047764618800886E-2,2.4061091783863803E-2,-3.2190000000000118E-3,1.5021999999999985E-2,-1.8241000000000014E-2,-8.9999999999999998E-4,4.1000000000000003E-3,-4.8999999999999998E-3,311,-67,55,1151,-248,204,null,null,1,9.3196644920782852,null,null,null,null,0,0,0,null,"Hypertension","Angiotensin II receptor blockers","Placebo","Mortality (N)",3.7,"10.73%",2.8989267209474461E-2,"0.97 (1.14 to 0.83)","3 fewer deaths per 1000 people treated for 3.7 year(s) (from 15 more to 18 fewer)","1 fewer deaths per 1000 people treated per year (from 4 more to 5 fewer)","Need to treat 311 people for 3.7 year(s) to prevent one death (from treating 67 people to cause one to treating 55 people to prevent one)","Need to treat 1151 people for 1 year to prevent one death (from treating 248 people to  cause one to treating 204 people to prevent one)","Need to treat 311 people for 3.7 year(s) to prevent one death (confidence intervals crossed the line of no effect)","Need to treat 1151 people for 1 year to prevent one death (confidence intervals crossed the line of no effect)","-0.32% absolute change in risk of death per 3.7 year(s) (from -1.82% to 1.5%)","-0.09% absolute change in risk of deaths per year (from -0.49% to 0.41%)","Offer antihypertensive drug treatment to people aged under 80 years with stage 1 hypertension who have one or more of target organ damage, established cardiovascular disease, renal disease, diabetes, a 10 year cardiovascular disease risk equivalent to 20% or greater. Offer antihypertensive drug treatment to any people of any age with stage 2 hypertension. ","Taken from recommendations 1.5.1 and 1.5.2 of the NICE guideline on hypertension in adults.  ","1 trial, mean age 76, mean starting BP 166/90"]
["Hypertension","Calcium channel blockers","Mortality","deaths","death",null,null,null,null,null,{"$f":"2.7*2.3","v":6.21},840,1.06,0.84,1.35,1.35,0.84,"N",1,-4,-22,10,-2,-10,4,6.5825999999999996E-2,8.3834999999999993E-2,5.2164000000000002E-2,2.8602964285714287E-2,3.6428303571428573E-2,2.2666500000000003E-2,3.7260000000000027E-3,2.1734999999999997E-2,-9.9359999999999987E-3,1.6000000000000001E-3,9.4000000000000004E-3,-4.3E-3,-268,-46,101,-617,-106,232,null,null,1,16.103059581320451,null,null,null,null,0,0,0,null,"Hypertension","Calcium channel blockers","Placebo","Mortality (N)",2.2999999999999998,"6.21%",2.6983928571428572E-2,"1.06 (1.35 to 0.84)","4 more deaths per 1000 people treated for 2.3 year(s) (from 22 more to 10 fewer)","2 more deaths per 1000 people treated per year (from 10 more to 4 fewer)","Need to treat 268 people for 2.3 year(s) to cause one death (from treating 46 people to cause one to treating 101 people to prevent one)","Need to treat 617 people for 1 year to cause one death (from treating 106 people to  cause one to treating 232 people to prevent one)","Need to treat 268 people for 2.3 year(s) to cause one death (confidence intervals crossed the line of no effect)","Need to treat 617 people for 1 year to cause one death (confidence intervals crossed the line of no effect)","0.37% absolute change in risk of death per 2.3 year(s) (from -0.99% to 2.17%)","0.16% absolute change in risk of deaths per year (from -0.43% to 0.94%)","Offer antihypertensive drug treatment to people aged under 80 years with stage 1 hypertension who have one or more of target organ damage, established cardiovascular disease, renal disease, diabetes, a 10 year cardiovascular disease risk equivalent to 20% or greater. Offer antihypertensive drug treatment to any people of any age with stage 2 hypertension. ","Taken from recommendations 1.5.1 and 1.5.2 of the NICE guideline on hypertension in adults.  ","1 trial, mean age 70, mean starting BP 174/86"]
["Hypertension","Beta blockers","Mortality","deaths","death",null,null,null,null,null,{"$f":"2.9*3.4","v":9.86},{"$f":"3.4*365","v":1241},0.94,0.83,1.06,1.06,0.83,"N",1,6,-6,17,2,-2,5,9.2684000000000002E-2,0.104516,8.1837999999999994E-2,2.7260000000000003E-2,3.074E-2,2.4069999999999998E-2,-5.9159999999999968E-3,5.9159999999999968E-3,-1.6761999999999996E-2,-1.6999999999999999E-3,1.6999999999999999E-3,-4.8999999999999998E-3,169,-169,60,575,-575,204,null,null,1,10.141987829614605,null,null,null,null,0,0,0,null,"Hypertension","Beta blockers","Placebo","Mortality (N)",3.4,"9.86%",2.8999999999999998E-2,"0.94 (1.06 to 0.83)","6 fewer deaths per 1000 people treated for 3.4 year(s) (from 6 more to 17 fewer)","2 fewer deaths per 1000 people treated per year (from 2 more to 5 fewer)","Need to treat 169 people for 3.4 year(s) to prevent one death (from treating 169 people to cause one to treating 60 people to prevent one)","Need to treat 575 people for 1 year to prevent one death (from treating 575 people to  cause one to treating 204 people to prevent one)","Need to treat 169 people for 3.4 year(s) to prevent one death (confidence intervals crossed the line of no effect)","Need to treat 575 people for 1 year to prevent one death (confidence intervals crossed the line of no effect)","-0.59% absolute change in risk of death per 3.4 year(s) (from -1.68% to 0.59%)","-0.17% absolute change in risk of deaths per year (from -0.49% to 0.17%)","Offer antihypertensive drug treatment to people aged under 80 years with stage 1 hypertension who have one or more of target organ damage, established cardiovascular disease, renal disease, diabetes, a 10 year cardiovascular disease risk equivalent to 20% or greater. Offer antihypertensive drug treatment to any people of any age with stage 2 hypertension. ","Taken from recommendations 1.5.1 and 1.5.2 of the NICE guideline on hypertension in adults.  ","7 trials, mean ages ranging from 69 to 76, mean starting BPs ranging from 158/91 to 196/99"]
["Type 2 Diabetes Mellitus (first line/monotherapy)","Metformin","Hypoglycaemia","episodes of hypoglycaemia","episode of hypoglycaemia",null,null,"Not reported",null,null,3.48,168,1.49,0.95,2.27,2.27,0.95,"N",1,-17,-44,2,-37,-96,4,{"$f":"($K53*M53)/100","v":5.1852000000000002E-2},{"$f":"($K53*P53)/100","v":7.8996000000000011E-2},{"$f":"($K53*Q53)/100","v":3.3059999999999999E-2},{"$f":"Z53/($L53/365)","v":0.11265464285714286},{"$f":"AA53/($L53/365)","v":0.17162821428571431},{"$f":"AB53/($L53/365)","v":7.1826785714285718E-2},1.7052000000000001E-2,4.4196000000000006E-2,-1.7399999999999994E-3,{"$f":"ROUND(AF53/($L53/365), 4)","v":3.6999999999999998E-2},{"$f":"ROUND(AG53/($L53/365), 4)","v":9.6000000000000002E-2},{"$f":"ROUND(AH53/($L53/365), 4)","v":-3.8E-3},-59,-23,575,-27,-11,265,null,null,{"$error":"#VALUE!"},{"$error":"#VALUE!"},null,1.5,0.95,2.33,1.4868733047016769,0.95083675021396985,2.2762867664155904,null,"Type 2 Diabetes Mellitus (first line/monotherapy)","Metformin","Placebo","Hypoglycaemia (N)",0.5,"3.48%",7.5607142857142845E-2,{"$f":"IF(M53=\"\", \"N/A\", CONCATENATE(M53, \" (\", P53, \" to \", Q53, \")\"))","v":"1.49 (2.27 to 0.95)"},"17 more episodes of hypoglycaemia per 1000 people treated for 0.5 year(s) (from 44 more to 2 fewer)","37 more episodes of hypoglycaemia per 1000 people treated per year (from 96 more to 4 fewer)","Need to treat 59 people for 0.5 year(s) to cause one episode of hypoglycaemia (from treating 23 people to cause one to treating 575 people to prevent one)","Need to treat 27 people for 1 year to cause one episode of hypoglycaemia (from treating 11 people to  cause one to treating 265 people to prevent one)","Need to treat 59 people for 0.5 year(s) to cause one episode of hypoglycaemia (confidence intervals crossed the line of no effect)","Need to treat 27 people for 1 year to cause one episode of hypoglycaemia (confidence intervals crossed the line of no effect)","1.71% absolute change in risk of episode of hypoglycaemia per 0.5 year(s) (from -0.17% to 4.42%)","3.7% absolute change in risk of episodes of hypoglycaemia per year (from -0.38% to 9.6%)","Offer standard-release metformin as the intial drug treatment for adults with T2DM. If metformin is contraindicated or not tolerated, consider initial drug treatment with a DPP-4 inhibitor, pioglitazone or a sulfonylurea. ","For full details see recommendations 1.6.19 and 1.6.23 of the NICE guideline on type 2 diabetes in adults.","4 trials, all as first line/monotherapy, mean ages ranging from 53-58, mean BMI ranging from 29-31, mean starting HbA1c ranging from 8-8.7"]
["Type 2 Diabetes Mellitus (first line/monotherapy)","Pioglitazone","Hypoglycaemia","episodes of hypoglycaemia","episode of hypoglycaemia",null,null,"Not reported",null,null,3.82,113,1.52,0.92,2.69,2.69,0.92,"N",1,-20,-65,3,-65,-210,10,{"$f":"($K54*M54)/100","v":5.8063999999999998E-2},{"$f":"($K54*P54)/100","v":0.10275799999999999},{"$f":"($K54*Q54)/100","v":3.5144000000000002E-2},{"$f":"Z54/($L54/365)","v":0.18755185840707964},{"$f":"AA54/($L54/365)","v":0.33191743362831855},{"$f":"AB54/($L54/365)","v":0.11351823008849558},1.9864000000000003E-2,6.4557999999999977E-2,-3.0559999999999967E-3,{"$f":"ROUND(AF54/($L54/365), 4)","v":6.4199999999999993E-2},{"$f":"ROUND(AG54/($L54/365), 4)","v":0.20849999999999999},{"$f":"ROUND(AH54/($L54/365), 4)","v":-9.9000000000000008E-3},-50,-15,327,-15,-5,101,null,null,{"$error":"#VALUE!"},{"$error":"#VALUE!"},null,1.54,0.92,2.79,1.5240220825728867,0.92142548530026647,2.6955741651341594,null,"Type 2 Diabetes Mellitus (first line/monotherapy)","Pioglitazone","Placebo","Hypoglycaemia (N)",0.3,"3.82%",0.12338938053097344,{"$f":"IF(M54=\"\", \"N/A\", CONCATENATE(M54, \" (\", P54, \" to \", Q54, \")\"))","v":"1.52 (2.69 to 0.92)"},"20 more episodes of hypoglycaemia per 1000 people treated for 0.3 year(s) (from 65 more to 3 fewer)","65 more episodes of hypoglycaemia per 1000 people treated per year (from 210 more to 10 fewer)","Need to treat 50 people for 0.3 year(s) to cause one episode of hypoglycaemia (from treating 15 people to cause one to treating 327 people to prevent one)","Need to treat 15 people for 1 year to cause one episode of hypoglycaemia (from treating 5 people to  cause one to treating 101 people to prevent one)","Need to treat 50 people for 0.3 year(s) to cause one episode of hypoglycaemia (confidence intervals crossed the line of no effect)","Need to treat 15 people for 1 year to cause one episode of hypoglycaemia (confidence intervals crossed the line of no effect)","1.99% absolute change in risk of episode of hypoglycaemia per 0.3 year(s) (from -0.31% to 6.46%)","6.42% absolute change in risk of episodes of hypoglycaemia per year (from -0.99% to 20.85%)","Offer standard-release metformin as the intial drug treatment for adults with T2DM. If metformin is contraindicated or not tolerated, consider initial drug treatment with a DPP-4 inhibitor, pioglitazone or a sulfonylurea. ","For full details see recommendations 1.6.19 and 1.6.23 of the NICE guideline on type 2 diabetes in adults.","3 trials, all as first line/monotherapy, mean ages ranging from 53-58, mean BMI ranging from 31-32 (not reported in one trial), mean starting HbA1c ranging from 7.5 to 10.3"]
["Type 2 Diabetes Mellitus (first line/monotherapy)","Sulfonylurea","Hypoglycaemia","episodes of hypoglycaemia","episode of hypoglycaemia",null,null,"Not reported",null,null,3.97,168,5.54,3.76,8.08,8.08,3.76,"N",0,-180,-281,-110,-391,-611,-239,{"$f":"($K55*M55)/100","v":0.21993799999999999},{"$f":"($K55*P55)/100","v":0.32077600000000006},{"$f":"($K55*Q55)/100","v":0.14927199999999999},{"$f":"Z55/($L55/365)","v":0.47784148809523808},{"$f":"AA55/($L55/365)","v":0.6969240476190478},{"$f":"AB55/($L55/365)","v":0.32431119047619045},0.18023800000000001,0.28107600000000005,0.10957199999999999,{"$f":"ROUND(AF55/($L55/365), 4)","v":0.3916},{"$f":"ROUND(AG55/($L55/365), 4)","v":0.61070000000000002},{"$f":"ROUND(AH55/($L55/365), 4)","v":0.23810000000000001},-6,-4,-9,-3,-2,-4,null,null,{"$error":"#VALUE!"},{"$error":"#VALUE!"},null,6.13,3.99,9.5500000000000007,5.538852968569155,3.7593625327051625,8.0810578109377769,null,"Type 2 Diabetes Mellitus (first line/monotherapy)","Sulfonylurea","Placebo","Hypoglycaemia (N)",0.5,"3.97%",8.6252976190476185E-2,{"$f":"IF(M55=\"\", \"N/A\", CONCATENATE(M55, \" (\", P55, \" to \", Q55, \")\"))","v":"5.54 (8.08 to 3.76)"},"180 more episodes of hypoglycaemia per 1000 people treated for 0.5 year(s) (from 281 more to 110 more)","391 more episodes of hypoglycaemia per 1000 people treated per year (from 611 more to 239 more)","Need to treat 6 people for 0.5 year(s) to cause one episode of hypoglycaemia (from treating 4 people to cause one to treating 9 people to cause one)","Need to treat 3 people for 1 year to cause one episode of hypoglycaemia (from treating 2 people to  cause one to treating 4 people to cause one)","Need to treat 6 people for 0.5 year(s) to cause one episode of hypoglycaemia (from treating 4 people to cause one to treating 9 people)","Need to treat 3 people for 1 year to cause one episode of hypoglycaemia (from treating 2 people to  cause one to treating 4 people)","18.02% absolute change in risk of episode of hypoglycaemia per 0.5 year(s) (from 10.96% to 28.11%)","39.16% absolute change in risk of episodes of hypoglycaemia per year (from 23.81% to 61.07%)","Offer standard-release metformin as the intial drug treatment for adults with T2DM. If metformin is contraindicated or not tolerated, consider initial drug treatment with a DPP-4 inhibitor, pioglitazone or a sulfonylurea. ","For full details see recommendations 1.6.19 and 1.6.23 of the NICE guideline on type 2 diabetes in adults.","4 trials, all as first line/monotherapy, mean ages ranging from 55-68, mean BMI ranging from 30-31 (not reported in two trials), mean starting HbA1c ranging from 7 to 8.4"]
["Type 2 Diabetes Mellitus (first line/monotherapy)","Linagliptin","Hypoglycaemia","episodes of hypoglycaemia","episode of hypoglycaemia",null,null,"Not reported",null,null,1.39,{"$f":"ROUND(365*0.46, 0)","v":168},0.6,0.11,2.57,2.57,0.11,"N",1,6,-22,12,13,-48,26,{"$f":"($K56*M56)/100","v":8.3400000000000002E-3},{"$f":"($K56*P56)/100","v":3.5722999999999991E-2},{"$f":"($K56*Q56)/100","v":1.5289999999999998E-3},{"$f":"Z56/($L56/365)","v":1.8119642857142858E-2},{"$f":"AA56/($L56/365)","v":7.7612470238095213E-2},{"$f":"AB56/($L56/365)","v":3.3219345238095234E-3},-5.559999999999999E-3,2.1822999999999995E-2,-1.2370999999999998E-2,{"$f":"ROUND(AF56/($L56/365), 4)","v":-1.21E-2},{"$f":"ROUND(AG56/($L56/365), 4)","v":4.7399999999999998E-2},{"$f":"ROUND(AH56/($L56/365), 4)","v":-2.69E-2},180,-46,81,83,-21,37,null,null,{"$error":"#VALUE!"},{"$error":"#VALUE!"},null,0.6,0.11,2.6,{"$f":"ROUND((1-EXP(AW56*LN(1-(K56/100))))/(K56/100), 2)","v":0.6},{"$f":"ROUND((1-EXP(AX56*LN(1-(K56/100))))/(K56/100), 2)","v":0.11},{"$f":"ROUND((1-EXP(AY56*LN(1-(K56/100))))/(K56/100), 2)","v":2.57},null,"Type 2 Diabetes Mellitus (first line/monotherapy)","Linagliptin","Placebo","Hypoglycaemia (N)",0.5,"1.39%",3.0199404761904757E-2,{"$f":"IF(M56=\"\", \"N/A\", CONCATENATE(M56, \" (\", P56, \" to \", Q56, \")\"))","v":"0.6 (2.57 to 0.11)"},"6 fewer episodes of hypoglycaemia per 1000 people treated for 0.5 year(s) (from 22 more to 12 fewer)","13 fewer episodes of hypoglycaemia per 1000 people treated per year (from 48 more to 26 fewer)","Need to treat 180 people for 0.5 year(s) to prevent one episode of hypoglycaemia (from treating 46 people to cause one to treating 81 people to prevent one)","Need to treat 83 people for 1 year to prevent one episode of hypoglycaemia (from treating 21 people to  cause one to treating 37 people to prevent one)","Need to treat 180 people for 0.5 year(s) to prevent one episode of hypoglycaemia (confidence intervals crossed the line of no effect)","Need to treat 83 people for 1 year to prevent one episode of hypoglycaemia (confidence intervals crossed the line of no effect)","-0.56% absolute change in risk of episode of hypoglycaemia per 0.5 year(s) (from -1.24% to 2.18%)","-1.21% absolute change in risk of episodes of hypoglycaemia per year (from -2.69% to 4.74%)","Offer standard-release metformin as the intial drug treatment for adults with T2DM. If metformin is contraindicated or not tolerated, consider initial drug treatment with a DPP-4 inhibitor, pioglitazone or a sulfonylurea. ","For full details see recommendations 1.6.19 and 1.6.23 of the NICE guideline on type 2 diabetes in adults.","1 trial, first line/monotherapy, mean age 53, mean BMI 29, mean starting HbA1c 8.7"]
["Type 2 Diabetes Mellitus (first line/monotherapy)","Saxagliptin","Hypoglycaemia","episodes of hypoglycaemia","episode of hypoglycaemia",null,null,"Not reported",null,null,0.7,{"$f":"ROUND(365*0.46, 0)","v":168},2.76,0.5,21.9,21.9,0.5,"N",1,-12,-146,4,-26,-317,9,1.9319999999999997E-2,0.15329999999999999,3.4999999999999996E-3,4.1974999999999991E-2,0.33306249999999998,7.6041666666666662E-3,1.2319999999999998E-2,0.14629999999999999,-3.4999999999999996E-3,2.6800000000000001E-2,0.31790000000000002,-7.6E-3,-81,-7,286,-37,-3,132,null,null,{"$error":"#VALUE!"},{"$error":"#VALUE!"},null,2.78,0.5,23.69,2.76,0.5,21.9,null,"Type 2 Diabetes Mellitus (first line/monotherapy)","Saxagliptin","Placebo","Hypoglycaemia (N)",0.5,"0.7%",1.5208333333333331E-2,"2.76 (21.9 to 0.5)","12 more episodes of hypoglycaemia per 1000 people treated for 0.5 year(s) (from 146 more to 4 fewer)","26 more episodes of hypoglycaemia per 1000 people treated per year (from 317 more to 9 fewer)","Need to treat 81 people for 0.5 year(s) to cause one episode of hypoglycaemia (from treating 7 people to cause one to treating 286 people to prevent one)","Need to treat 37 people for 1 year to cause one episode of hypoglycaemia (from treating 3 people to  cause one to treating 132 people to prevent one)","Need to treat 81 people for 0.5 year(s) to cause one episode of hypoglycaemia (confidence intervals crossed the line of no effect)","Need to treat 37 people for 1 year to cause one episode of hypoglycaemia (confidence intervals crossed the line of no effect)","1.23% absolute change in risk of episode of hypoglycaemia per 0.5 year(s) (from -0.35% to 14.63%)","2.68% absolute change in risk of episodes of hypoglycaemia per year (from -0.76% to 31.79%)","Offer standard-release metformin as the intial drug treatment for adults with T2DM. If metformin is contraindicated or not tolerated, consider initial drug treatment with a DPP-4 inhibitor, pioglitazone or a sulfonylurea. ","For full details see recommendations 1.6.19 and 1.6.23 of the NICE guideline on type 2 diabetes in adults.","1 trial, first line/monotherapy, mean age 51, mean BMI 26, mean starting HbA1c 8.2"]
["Type 2 Diabetes Mellitus (first line/monotherapy)","Sitagliptin","Hypoglycaemia","episodes of hypoglycaemia","episode of hypoglycaemia",null,null,"Not reported",null,null,0.4,{"$f":"ROUND(365*0.23, 0)","v":84},1.23,0.74,2.06,2.06,0.74,"N",1,-1,-4,1,-4,-17,4,4.9199999999999999E-3,8.2400000000000008E-3,2.96E-3,2.1378571428571427E-2,3.5804761904761909E-2,1.2861904761904762E-2,9.199999999999997E-4,4.2400000000000007E-3,-1.0400000000000003E-3,4.0000000000000001E-3,1.84E-2,-4.4999999999999997E-3,-1087,-236,962,-250,-54,221,null,null,{"$error":"#VALUE!"},{"$error":"#VALUE!"},null,1.23,0.74,2.06,1.23,0.74,2.06,null,"Type 2 Diabetes Mellitus (first line/monotherapy)","Sitagliptin","Placebo","Hypoglycaemia (N)",0.2,"0.4%",1.7380952380952382E-2,"1.23 (2.06 to 0.74)","1 more episodes of hypoglycaemia per 1000 people treated for 0.2 year(s) (from 4 more to 1 fewer)","4 more episodes of hypoglycaemia per 1000 people treated per year (from 17 more to 4 fewer)","Need to treat 1087 people for 0.2 year(s) to cause one episode of hypoglycaemia (from treating 236 people to cause one to treating 962 people to prevent one)","Need to treat 250 people for 1 year to cause one episode of hypoglycaemia (from treating 54 people to  cause one to treating 221 people to prevent one)","Need to treat 1087 people for 0.2 year(s) to cause one episode of hypoglycaemia (confidence intervals crossed the line of no effect)","Need to treat 250 people for 1 year to cause one episode of hypoglycaemia (confidence intervals crossed the line of no effect)","0.09% absolute change in risk of episode of hypoglycaemia per 0.2 year(s) (from -0.1% to 0.42%)","0.4% absolute change in risk of episodes of hypoglycaemia per year (from -0.45% to 1.84%)","Offer standard-release metformin as the intial drug treatment for adults with T2DM. If metformin is contraindicated or not tolerated, consider initial drug treatment with a DPP-4 inhibitor, pioglitazone or a sulfonylurea. ","For full details see recommendations 1.6.19 and 1.6.23 of the NICE guideline on type 2 diabetes in adults.","6 trials, all as first line/monotherapy, mean ages ranging from 53-56, mean BMI ranging from 31-32 (not reported in one trials), mean starting HbA1c ranging from 7.7 to 8"]
["Type 2 Diabetes Mellitus (first line/monotherapy)","Vildagliptin","Hypoglycaemia","episodes of hypoglycaemia","episode of hypoglycaemia",null,null,"Not reported",null,null,1.33,{"$f":"ROUND(365*0.23, 0)","v":84},1.1200000000000001,0.55000000000000004,2.33,2.33,0.55000000000000004,"N",1,-2,-18,6,-9,-78,26,1.4896000000000003E-2,3.0989000000000003E-2,7.3150000000000012E-3,6.4726666666666682E-2,0.13465458333333336,3.178541666666667E-2,1.5960000000000019E-3,1.7689000000000003E-2,-5.984999999999999E-3,6.8999999999999999E-3,7.6899999999999996E-2,-2.5999999999999999E-2,-627,-57,167,-144,-13,38,null,null,{"$error":"#VALUE!"},{"$error":"#VALUE!"},null,1.1200000000000001,0.55000000000000004,2.35,1.1200000000000001,0.55000000000000004,2.33,null,"Type 2 Diabetes Mellitus (first line/monotherapy)","Vildagliptin","Placebo","Hypoglycaemia (N)",0.2,"1.33%",5.7791666666666665E-2,"1.12 (2.33 to 0.55)","2 more episodes of hypoglycaemia per 1000 people treated for 0.2 year(s) (from 18 more to 6 fewer)","9 more episodes of hypoglycaemia per 1000 people treated per year (from 78 more to 26 fewer)","Need to treat 627 people for 0.2 year(s) to cause one episode of hypoglycaemia (from treating 57 people to cause one to treating 167 people to prevent one)","Need to treat 144 people for 1 year to cause one episode of hypoglycaemia (from treating 13 people to  cause one to treating 38 people to prevent one)","Need to treat 627 people for 0.2 year(s) to cause one episode of hypoglycaemia (confidence intervals crossed the line of no effect)","Need to treat 144 people for 1 year to cause one episode of hypoglycaemia (confidence intervals crossed the line of no effect)","0.16% absolute change in risk of episode of hypoglycaemia per 0.2 year(s) (from -0.6% to 1.77%)","0.69% absolute change in risk of episodes of hypoglycaemia per year (from -2.6% to 7.69%)","Offer standard-release metformin as the intial drug treatment for adults with T2DM. If metformin is contraindicated or not tolerated, consider initial drug treatment with a DPP-4 inhibitor, pioglitazone or a sulfonylurea. ","For full details see recommendations 1.6.19 and 1.6.23 of the NICE guideline on type 2 diabetes in adults.","5 trials, all as first line/monotherapy, mean ages ranging from 54-59, mean BMI ranging from 25-33, mean starting HbA1c ranging from 7.7 to 9"]
["Type 2 Diabetes Mellitus (first line/monotherapy)","Metformin","Stopping therapy due to adverse events","cessations of treatment due to adverse events","cessation of treatment due to adverse events",null,null,"Not reported",null,null,2.44,186,1.45,1.1100000000000001,1.91,1.91,1.1100000000000001,"N",0,-11,-22,-3,-22,-43,-6,3.5379999999999995E-2,4.6604E-2,2.7084E-2,6.9428494623655898E-2,9.1454086021505371E-2,5.3148709677419352E-2,1.0979999999999998E-2,2.2204000000000002E-2,2.6840000000000019E-3,2.1499999999999998E-2,4.36E-2,5.3E-3,-91,-45,-373,-46,-23,-190,null,null,{"$error":"#VALUE!"},{"$error":"#VALUE!"},null,1.46,1.1100000000000001,1.93,1.45,1.1100000000000001,1.91,null,"Type 2 Diabetes Mellitus (first line/monotherapy)","Metformin","Placebo","Stopping therapy due to adverse events (N)",0.5,"2.44%",4.7881720430107529E-2,"1.45 (1.91 to 1.11)","11 more cessations of treatment due to adverse events per 1000 people treated for 0.5 year(s) (from 22 more to 3 more)","22 more cessations of treatment due to adverse events per 1000 people treated per year (from 43 more to 6 more)","Need to treat 91 people for 0.5 year(s) to cause one cessation of treatment due to adverse events (from treating 45 people to cause one to treating 373 people to cause one)","Need to treat 46 people for 1 year to cause one cessation of treatment due to adverse events (from treating 23 people to  cause one to treating 190 people to cause one)","Need to treat 91 people for 0.5 year(s) to cause one cessation of treatment due to adverse events (from treating 45 people to cause one to treating 373 people)","Need to treat 46 people for 1 year to cause one cessation of treatment due to adverse events (from treating 23 people to  cause one to treating 190 people)","1.1% absolute change in risk of cessation of treatment due to adverse events per 0.5 year(s) (from 0.27% to 2.22%)","2.15% absolute change in risk of cessations of treatment due to adverse events per year (from 0.53% to 4.36%)","Offer standard-release metformin as the intial drug treatment for adults with T2DM. If metformin is contraindicated or not tolerated, consider initial drug treatment with a DPP-4 inhibitor, pioglitazone or a sulfonylurea. ","For full details see recommendations 1.6.19 and 1.6.23 of the NICE guideline on type 2 diabetes in adults.","4 trials, all as first line/monotherapy, mean ages ranging from 53-58, mean BMI ranging from 29-31, mean starting HbA1c ranging from 8-8.7"]
["Type 2 Diabetes Mellitus (first line/monotherapy)","Pioglitazone","Stopping therapy due to adverse events","cessations of treatment due to adverse events","cessation of treatment due to adverse events",null,null,"Not reported",null,null,2.31,183,1.6,1.1499999999999999,2.2200000000000002,2.2200000000000002,1.1499999999999999,"N",0,-14,-28,-3,-28,-56,-6,3.696E-2,5.1282000000000008E-2,2.6564999999999998E-2,7.371803278688524E-2,0.10228377049180329,5.2984836065573762E-2,1.3860000000000001E-2,2.8182000000000006E-2,3.464999999999998E-3,2.76E-2,5.62E-2,6.8999999999999999E-3,-72,-35,-289,-36,-18,-145,null,null,{"$error":"#VALUE!"},{"$error":"#VALUE!"},null,1.61,1.1499999999999999,2.25,1.6,1.1499999999999999,2.2200000000000002,null,"Type 2 Diabetes Mellitus (first line/monotherapy)","Pioglitazone","Placebo","Stopping therapy due to adverse events (N)",0.5,"2.31%",4.6073770491803279E-2,"1.6 (2.22 to 1.15)","14 more cessations of treatment due to adverse events per 1000 people treated for 0.5 year(s) (from 28 more to 3 more)","28 more cessations of treatment due to adverse events per 1000 people treated per year (from 56 more to 6 more)","Need to treat 72 people for 0.5 year(s) to cause one cessation of treatment due to adverse events (from treating 35 people to cause one to treating 289 people to cause one)","Need to treat 36 people for 1 year to cause one cessation of treatment due to adverse events (from treating 18 people to  cause one to treating 145 people to cause one)","Need to treat 72 people for 0.5 year(s) to cause one cessation of treatment due to adverse events (from treating 35 people to cause one to treating 289 people)","Need to treat 36 people for 1 year to cause one cessation of treatment due to adverse events (from treating 18 people to  cause one to treating 145 people)","1.39% absolute change in risk of cessation of treatment due to adverse events per 0.5 year(s) (from 0.35% to 2.82%)","2.76% absolute change in risk of cessations of treatment due to adverse events per year (from 0.69% to 5.62%)","Offer standard-release metformin as the intial drug treatment for adults with T2DM. If metformin is contraindicated or not tolerated, consider initial drug treatment with a DPP-4 inhibitor, pioglitazone or a sulfonylurea. ","For full details see recommendations 1.6.19 and 1.6.23 of the NICE guideline on type 2 diabetes in adults.","3 trials, all as first line/monotherapy, mean ages ranging from 53-58, mean BMI ranging from 31-32 (not reported in one trial), mean starting HbA1c ranging from 7.5 to 10.3"]
["Type 2 Diabetes Mellitus (first line/monotherapy)","Sulfonylurea","Stopping therapy due to adverse events","cessations of treatment due to adverse events","cessation of treatment due to adverse events",null,null,"Not reported",null,null,5.94,168,1.69,1.28,2.2400000000000002,2.2400000000000002,1.28,"N",0,-41,-74,-17,-89,-161,-37,0.100386,0.13305600000000001,7.6032000000000016E-2,0.21810053571428573,0.28908,0.16518857142857146,4.0986000000000002E-2,7.3656000000000013E-2,1.6632000000000008E-2,8.8999999999999996E-2,0.16,3.61E-2,-24,-14,-60,-11,-6,-28,null,null,{"$error":"#VALUE!"},{"$error":"#VALUE!"},null,1.73,1.29,2.33,1.69,1.28,2.2400000000000002,null,"Type 2 Diabetes Mellitus (first line/monotherapy)","Sulfonylurea","Placebo","Stopping therapy due to adverse events (N)",0.5,"5.94%",0.12905357142857143,"1.69 (2.24 to 1.28)","41 more cessations of treatment due to adverse events per 1000 people treated for 0.5 year(s) (from 74 more to 17 more)","89 more cessations of treatment due to adverse events per 1000 people treated per year (from 161 more to 37 more)","Need to treat 24 people for 0.5 year(s) to cause one cessation of treatment due to adverse events (from treating 14 people to cause one to treating 60 people to cause one)","Need to treat 11 people for 1 year to cause one cessation of treatment due to adverse events (from treating 6 people to  cause one to treating 28 people to cause one)","Need to treat 24 people for 0.5 year(s) to cause one cessation of treatment due to adverse events (from treating 14 people to cause one to treating 60 people)","Need to treat 11 people for 1 year to cause one cessation of treatment due to adverse events (from treating 6 people to  cause one to treating 28 people)","4.1% absolute change in risk of cessation of treatment due to adverse events per 0.5 year(s) (from 1.66% to 7.37%)","8.9% absolute change in risk of cessations of treatment due to adverse events per year (from 3.61% to 16%)","Offer standard-release metformin as the intial drug treatment for adults with T2DM. If metformin is contraindicated or not tolerated, consider initial drug treatment with a DPP-4 inhibitor, pioglitazone or a sulfonylurea. ","For full details see recommendations 1.6.19 and 1.6.23 of the NICE guideline on type 2 diabetes in adults.","4 trials, all as first line/monotherapy, mean ages ranging from 55-68, mean BMI ranging from 30-31 (not reported in two trials), mean starting HbA1c ranging from 7 to 8.4"]
["Type 2 Diabetes Mellitus (first line/monotherapy)","Linagliptin","Stopping therapy due to adverse events","cessations of treatment due to adverse events","cessation of treatment due to adverse events",null,null,"Not reported",null,null,4.17,{"$f":"ROUND(365*0.34, 0)","v":124},0.81,0.34,1.85,1.85,0.34,"N",1,8,-35,28,24,-103,82,3.3777000000000001E-2,7.7145000000000005E-2,1.4178000000000001E-2,9.9424233870967743E-2,0.22708004032258067,4.1733629032258072E-2,-7.922999999999996E-3,3.5445000000000004E-2,-2.7521999999999998E-2,-2.3300000000000001E-2,0.1043,-8.1000000000000003E-2,126,-28,36,43,-10,12,null,null,{"$error":"#VALUE!"},{"$error":"#VALUE!"},null,0.81,0.34,1.88,0.81,0.34,1.85,null,{"$f":"A63","v":"Type 2 Diabetes Mellitus (first line/monotherapy)"},{"$f":"B63","v":"Linagliptin"},"Placebo","Stopping therapy due to adverse events (N)",0.3,"4.17%",0.12274596774193547,"0.81 (1.85 to 0.34)","8 fewer cessations of treatment due to adverse events per 1000 people treated for 0.3 year(s) (from 35 more to 28 fewer)","24 fewer cessations of treatment due to adverse events per 1000 people treated per year (from 103 more to 82 fewer)","Need to treat 126 people for 0.3 year(s) to prevent one cessation of treatment due to adverse events (from treating 28 people to cause one to treating 36 people to prevent one)","Need to treat 43 people for 1 year to prevent one cessation of treatment due to adverse events (from treating 10 people to  cause one to treating 12 people to prevent one)","Need to treat 126 people for 0.3 year(s) to prevent one cessation of treatment due to adverse events (confidence intervals crossed the line of no effect)","Need to treat 43 people for 1 year to prevent one cessation of treatment due to adverse events (confidence intervals crossed the line of no effect)","-0.79% absolute change in risk of cessation of treatment due to adverse events per 0.3 year(s) (from -2.75% to 3.54%)","-2.33% absolute change in risk of cessations of treatment due to adverse events per year (from -8.1% to 10.43%)","Offer standard-release metformin as the intial drug treatment for adults with T2DM. If metformin is contraindicated or not tolerated, consider initial drug treatment with a DPP-4 inhibitor, pioglitazone or a sulfonylurea. ","For full details see recommendations 1.6.19 and 1.6.23 of the NICE guideline on type 2 diabetes in adults.","3 trials, all as first line/monotherapy, mean ages ranging from 53-60, mean BMI ranging from 24-30, mean starting HbA1c ranging from 8.1 to 8.7"]
["Type 2 Diabetes Mellitus (first line/monotherapy)","Saxagliptin","Stopping therapy due to adverse events","cessations of treatment due to adverse events","cessation of treatment due to adverse events",null,null,"Not reported",null,null,1.06,{"$f":"ROUND(365*0.46, 0)","v":168},1.01,0.17,5.63,5.63,0.17,"N",1,0,-49,9,0,-106,20,1.0706E-2,5.9678000000000002E-2,1.8020000000000002E-3,2.3260059523809523E-2,0.12965755952380953,3.9150595238095246E-3,1.0599999999999943E-4,4.9077999999999997E-2,-8.7980000000000003E-3,2.0000000000000001E-4,0.1066,-1.9099999999999999E-2,-9434,-20,114,-4342,-9,52,null,null,{"$error":"#VALUE!"},{"$error":"#VALUE!"},null,1.01,0.17,5.77,1.01,0.17,5.63,null,"Type 2 Diabetes Mellitus (first line/monotherapy)","Saxagliptin","Placebo","Stopping therapy due to adverse events (N)",0.5,"1.06%",2.3029761904761904E-2,"1.01 (5.63 to 0.17)","0 more cessations of treatment due to adverse events per 1000 people treated for 0.5 year(s) (from 49 more to 9 fewer)","0 more cessations of treatment due to adverse events per 1000 people treated per year (from 106 more to 20 fewer)","Need to treat 9434 people for 0.5 year(s) to cause one cessation of treatment due to adverse events (from treating 20 people to cause one to treating 114 people to prevent one)","Need to treat 4342 people for 1 year to cause one cessation of treatment due to adverse events (from treating 9 people to  cause one to treating 52 people to prevent one)","Need to treat 9434 people for 0.5 year(s) to cause one cessation of treatment due to adverse events (confidence intervals crossed the line of no effect)","Need to treat 4342 people for 1 year to cause one cessation of treatment due to adverse events (confidence intervals crossed the line of no effect)","0.01% absolute change in risk of cessation of treatment due to adverse events per 0.5 year(s) (from -0.88% to 4.91%)","0.02% absolute change in risk of cessations of treatment due to adverse events per year (from -1.91% to 10.66%)","Offer standard-release metformin as the intial drug treatment for adults with T2DM. If metformin is contraindicated or not tolerated, consider initial drug treatment with a DPP-4 inhibitor, pioglitazone or a sulfonylurea. ","For full details see recommendations 1.6.19 and 1.6.23 of the NICE guideline on type 2 diabetes in adults.","1 trial, first line/monotherapy, mean age 51, mean BMI 26, mean starting HbA1c 8.2"]
["Type 2 Diabetes Mellitus (first line/monotherapy)","Sitagliptin","Stopping therapy due to adverse events","cessations of treatment due to adverse events","cessation of treatment due to adverse events",null,null,"Not reported",null,null,2.88,{"$f":"ROUND(365*0.23, 0)","v":84},1.04,0.73,1.48,1.48,0.73,"N",1,-1,-14,8,-4,-61,35,2.9951999999999999E-2,4.2623999999999995E-2,2.1023999999999998E-2,0.13014857142857142,0.18521142857142855,9.1354285714285707E-2,1.152000000000002E-3,1.3823999999999996E-2,-7.7760000000000008E-3,5.0000000000000001E-3,6.0100000000000001E-2,-3.3799999999999997E-2,-868,-72,129,-200,-17,30,null,null,{"$error":"#VALUE!"},{"$error":"#VALUE!"},null,1.04,0.73,1.49,1.04,0.73,1.48,null,"Type 2 Diabetes Mellitus (first line/monotherapy)","Sitagliptin","Placebo","Stopping therapy due to adverse events (N)",0.2,"2.88%",0.12514285714285711,"1.04 (1.48 to 0.73)","1 more cessations of treatment due to adverse events per 1000 people treated for 0.2 year(s) (from 14 more to 8 fewer)","4 more cessations of treatment due to adverse events per 1000 people treated per year (from 61 more to 35 fewer)","Need to treat 868 people for 0.2 year(s) to cause one cessation of treatment due to adverse events (from treating 72 people to cause one to treating 129 people to prevent one)","Need to treat 200 people for 1 year to cause one cessation of treatment due to adverse events (from treating 17 people to  cause one to treating 30 people to prevent one)","Need to treat 868 people for 0.2 year(s) to cause one cessation of treatment due to adverse events (confidence intervals crossed the line of no effect)","Need to treat 200 people for 1 year to cause one cessation of treatment due to adverse events (confidence intervals crossed the line of no effect)","0.12% absolute change in risk of cessation of treatment due to adverse events per 0.2 year(s) (from -0.78% to 1.38%)","0.5% absolute change in risk of cessations of treatment due to adverse events per year (from -3.38% to 6.01%)","Offer standard-release metformin as the intial drug treatment for adults with T2DM. If metformin is contraindicated or not tolerated, consider initial drug treatment with a DPP-4 inhibitor, pioglitazone or a sulfonylurea. ","For full details see recommendations 1.6.19 and 1.6.23 of the NICE guideline on type 2 diabetes in adults.","9 trials, all as first line/monotherapy, mean ages ranging from 51-72, mean BMI ranging from 25-31 (not reported in one trials), mean starting HbA1c ranging from 7.6 to 8.7"]
["Type 2 Diabetes Mellitus (first line/monotherapy)","Vildagliptin","Stopping therapy due to adverse events","cessations of treatment due to adverse events","cessation of treatment due to adverse events",null,null,"Not reported",null,null,3.51,{"$f":"ROUND(365*0.345, 0)","v":126},0.99,0.69,1.41,1.41,0.69,"N",1,0,-14,11,0,-41,32,3.4749000000000002E-2,4.9490999999999993E-2,2.4218999999999994E-2,0.10066178571428572,0.14336678571428568,7.0158214285714268E-2,-3.509999999999991E-4,1.4390999999999998E-2,-1.0881000000000004E-2,-1E-3,4.1700000000000001E-2,-3.15E-2,2849,-69,92,983,-24,32,null,null,{"$error":"#VALUE!"},{"$error":"#VALUE!"},null,0.99,0.69,1.42,0.99,0.69,1.41,null,"Type 2 Diabetes Mellitus (first line/monotherapy)","Vildagliptin","Placebo","Stopping therapy due to adverse events (N)",0.3,"3.51%",0.10167857142857142,"0.99 (1.41 to 0.69)","0 more cessations of treatment due to adverse events per 1000 people treated for 0.3 year(s) (from 14 more to 11 fewer)","0 more cessations of treatment due to adverse events per 1000 people treated per year (from 41 more to 32 fewer)","Need to treat 2849 people for 0.3 year(s) to prevent one cessation of treatment due to adverse events (from treating 69 people to cause one to treating 92 people to prevent one)","Need to treat 983 people for 1 year to prevent one cessation of treatment due to adverse events (from treating 24 people to  cause one to treating 32 people to prevent one)","Need to treat 2849 people for 0.3 year(s) to prevent one cessation of treatment due to adverse events (confidence intervals crossed the line of no effect)","Need to treat 983 people for 1 year to prevent one cessation of treatment due to adverse events (confidence intervals crossed the line of no effect)","-0.04% absolute change in risk of cessation of treatment due to adverse events per 0.3 year(s) (from -1.09% to 1.44%)","-0.1% absolute change in risk of cessations of treatment due to adverse events per year (from -3.15% to 4.17%)","Offer standard-release metformin as the intial drug treatment for adults with T2DM. If metformin is contraindicated or not tolerated, consider initial drug treatment with a DPP-4 inhibitor, pioglitazone or a sulfonylurea. ","For full details see recommendations 1.6.19 and 1.6.23 of the NICE guideline on type 2 diabetes in adults.","6 trials, all as first line/monotherapy, mean ages ranging from 51-59, mean BMI ranging from 25-33, mean starting HbA1c ranging from 7.7 to 9"]